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ABSTRACT 
 
Unaccustomed exercise consisting of eccentric contractions induces muscle damage that is 
characterised by muscle weakness, soreness, swelling and increased muscle stiffness. These 
symptoms affect daily activities and athletic performance; therefore, interventions to attenuate the 
symptoms and enhance recovery from muscle damage are necessary. Pulsed electromagnetic field 
therapy (PEMFT) is anecdotally reported to increase muscle blood flow and oxygenation to 
enhance tissue healing. One previous study showed that PEMFT was effective for alleviating 
muscle soreness and losses in range of motion after exercise. However, studies investigating the 
effect of PEMFT on recovery of muscle strength following eccentric exercise are lacking. The 
purposes of this study were to investigate the effects of PEMFT treatment on muscle temperature, 
blood flow and oxygenation (Study 1), and on the symptoms associated with eccentric exercise-
induced muscle damage (Study 2).  
In Study 1, the effects of 30 min PEMFT on muscle temperature, blood flow and oxygenation 
were examined using nine healthy men (23.6 ± 3.7 years). A device called e-cell™was used for 
PEMFT in this study, which is the size and shape of a computer mouse weighing approximately 140 
g, and sham treatment used a visually identical device without pulsed electromagnetic field 
production. PEMFT was applied over the bicep brachii of one arm for 30 min, and the other arm 
received sham treatment, while each subject was lying supine on a massage table. The device was 
marked A or B; thus, both the investigator and subjects were blinded as to which device was active 
e-cell™ or sham, and the use of dominant or non-dominant arm for device A or B was randomised 
and counterbalanced among subjects. Pre-treatment muscle temperature was measured by a 
thermistor needle (22 gauge, 70 mm) inserted to a depth of 20 mm at 10 mm laterally adjacent to a 
near infrared spectroscopy (NIRS) probe unit that was attached to the skin at the mid-belly of the 
biceps brachii, and the post-treatment measurement was taken at 5 mm proximal to the first site. 
 v 
The NIRS was used to measure tissue oxygenation index (TOI), a measure of muscle oxygenation, 
and total haemoglobin content (tHb), an indirect measure of blood flow, which were recorded 
throughout the treatment period. Changes in muscle temperature from before to immediately post-
treatment were compared between e-cell™ and sham conditions using a paired t-test, and changes in 
TOI and tHb from baseline to 30 min of treatment (0, 10, 20 and 30 min) were compared between 
conditions by a two-way repeated measures analysis of variance (ANOVA). Muscle temperature 
significantly (p<0.05) increased after e-cell™ treatment only and was 0.55 ± 0.22°C higher 
(p=0.033) for the arm that received e-cell™ than sham treatment. No significant changes in TOI and 
tHb were evident for either condition.  
In Study 2, eight men and eight women (24.8 ± 6.2 years) performed two bouts of 60 maximal 
isokinetic (30°⋅s-1) eccentric contractions of the elbow flexors on each arm separated by 4 weeks. In 
each eccentric contraction, the elbow joint was forcibly extended from a flexed (90°) to a fully 
extended position (0°). At immediately after, and 1-4 days following the exercise, the exercised arm 
received 30 min of either e-cell™ or sham treatment described above. The arm dominance and the 
order of treatment conditions were randomised and counterbalanced among the subjects, and the 
study was conducted in a double-blinded manner. Dependant variables included maximal voluntary 
contraction (MVC) strength, range of motion (ROM), upper arm circumference (CIR), muscle 
soreness by a visual analogue scale, muscle tenderness measured by pressure pain threshold (PPT) 
and plasma CK activity. Changes in these variables for 7 days following the exercise were 
compared between e-cell™ and sham treatment conditions, men and women, and the first and 
second bouts of exercise by a two-way repeated measures ANOVA. The changes in the variables 
from pre- to post-treatment were also analysed by a two-way repeated measures ANOVA. All 
variables changed significantly (p<0.05) following eccentric exercise; however, the changes in the 
variables over time were not significantly different between men and women. Thus, men and 
women were combined for subsequent analyses. For the acute changes in the variables from pre- to 
post-treatment, no significant differences in any variables were evident between e-cell™ and sham 
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conditions. A significant (p<0.05) reduction in MVC by 8% was observed for both conditions, but 
no significant changes were found for other variables. Regarding the changes in the variables 1-7 
days following exercise, the rate of recovery for MVC strength and ROM was significantly 
enhanced, and increases in muscle soreness, CIR and plasma CK activity were significantly 
attenuated for the e-cell™ compared with sham condition. When comparing the first and second 
bouts by ignoring the treatment, MVC strength and ROM recovered significantly faster, and 
increases in CIR and muscle soreness were significantly smaller for bout 2 compared with bout 1, 
and these effects were similar or greater than those produced by e-cell™.  It was concluded that e-
cell™ treatment enhanced the recovery of muscle damage; however, the magnitude of recovery 
following e-cell™ and sham treatment was influenced in the second bout of exercise by the 
contralateral repeated bout effect. Furthermore, pre-conditioning the muscle with non-damaging 
exercise could be more effective for attenuating symptoms associated with exercise-induced muscle 
damage compared to e-cell™ treatment. 
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CHAPTER ONE 
INTRODUCTION 
1.1 Background 
Muscle damage occurs when receiving harmful physical, chemical or biological stimulus. In 
exercise and sports or daily activities, muscle damage induced by eccentric contractions is most 
common. Downhill running (Byrnes et al., 1985) or walking (Balnave & Thompson, 1993) and 
bench stepping (Gleeson, Blannin, Walsh, Field, & Pritchard, 1998) are used to experimentally 
induce muscle damage in humans. Other frequently used eccentric exercise models include 
maximal or sub-maximal eccentric exercise of the knee extensors (Kellis & Baltzopoulos, 1998) 
and flexors (Johansson, Lindstrom, Sundelin, & Lindstrom, 1999) as well as the elbow flexors 
(Chapman, Newton, Sacco, & Nosaka, 2006). Among them, the elbow flexor model is most often 
used in many previous studies (e.g. Chen et al., 2011; Clarkson & Tremblay, 1988; Cleak & Eston, 
1992; Jones, Newham, & Clarkson, 1987).  
After performing “unaccustomed” eccentric exercise, muscles become weak, sore, swollen 
and stiff for several days (Chen, Lin, Chen, Lin, & Nosaka, 2011; Cleak & Eston, 1992; Nosaka & 
Clarkson, 1995; Nosaka, Newton, & Sacco, 2002). To quantify these symptoms, maximal voluntary 
contraction (MVC) strength, pain scale, limb circumference or muscle thickness, and range of 
motion (ROM) are often used. Other markers of muscle damage include muscle proteins (e.g. 
creatine kinase: CK, myoglobin) in the blood, and abnormality detected by ultrasound or magnetic 
resonance images (Clarkson & Hubal, 2002; Fleckenstein & Shellock, 1992; Nosaka, Muthalib, 
Lavender, & Laursen, 2007). It is important to note that these markers do not necessarily correlate 
with one another. For example, muscle soreness does not develop immediately following eccentric 
exercise of the elbow flexors but at the same time the greatest decreases in muscle strength loss are 
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apparent (Nosaka, 2008). Nosaka et al. (2002) reported that the magnitude of muscle soreness did 
not correlate with the magnitude of decrease in maximal isometric strength and range of motion, 
increases in upper arm circumference and plasma CK activity. Consequently, it appears that there 
are several aspects to eccentric exercise-induced muscle damage (EIMD). 
The magnitude of muscle damage incurred after eccentric exercise depends on the training 
status of an individual, the force and velocity of contractions, number of repetitions and range of 
movement (Chapman, et al., 2006; Cheung, Hume, & Maxwell, 2003; Connolly, Sayers, & 
McHugh, 2003; Nosaka & Sakamoto, 2001). Nosaka and Clarkson (1996) reported that it took more 
than two months for muscle strength to fully return to baseline levels when untrained individuals 
performed maximal eccentric exercise of the elbow flexors. In contrast, Newton and colleagues 
(2008) demonstrated that resistance trained men had smaller decreases in muscle strength after 
exercise compared with men who had little experience in resistance training, and muscle strength 
fully recovered by 3 days following 60 maximal eccentric contractions of the elbow flexors. 
Previous studies have demonstrated that the magnitude of muscle damage is greater when greater 
force is produced (Nosaka & Newton, 2002), a larger number of contractions are performed 
(Chapman, et al., 2006), muscle is stretched more (Nosaka & Sakamoto, 2001) and contraction 
velocity is faster (Chapman, Newton, Mcguigan, & Nosaka, 2008).  
There are also studies that report gender differences exist for the changes in muscle damage 
markers. For example, Seawright et al. (2008) compared the muscle damage markers between 58 
women and 42 men after 50 maximal eccentric contractions of the elbow flexors, and reported that 
women showed greater relative strength losses than men immediately after exercise, but men had 
significantly higher peak CK activity than women.  In contrast, Rinard and associates (2000) 
showed that gender had no significant effect on muscle damage markers following 70 maximal 
eccentric contractions of the elbow flexors performed by 83 women and 82 men. Therefore, it 
remains unclear as to whether gender affects the magnitude of eccentric exercise-induced muscle 
damage.  
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Since muscle damage is often inevitable, therapeutic interventions are needed to alleviate the 
symptoms of muscle damage and facilitate the recovery process. Several different types of 
interventions have been investigated for their efficacy on the symptoms and markers of muscle 
damage experimentally induced by various eccentric exercises. Some examples of interventions 
include eccentric contractions, cryotherapy (ice massage, ice packs), electrotherapies (ultrasound, 
transcutaneous electrical nerve stimulation: TENS, diathermy), physical therapies (stretching, 
massage, compression), nutritional supplements and non-steroidal anti-inflammatory drugs among 
others (Allen, Mattacola, & Perrin, 1999; Burgess & Lambert, 2010; Cheung, et al., 2003; 
Connolly, et al., 2003; Howatson & van Someren, 2008). As explained previously, symptoms 
associated with EIMD are dissimilar in that they typically peak on separate days; nevertheless, 
therapeutic modalities should primarily focus on attenuate delayed onset muscle soreness (DOMS) 
and enhancing the recovery of muscle function after exercise, since these aspects of EIMD can 
directly affect daily activities and athletic performance.  
The effect of therapeutic interventions in the treatment of EIMD of the elbow flexors has 
previously been investigated. Some examples include, deeply applied sport massage (10 minutes 
effleurage and petrissage) that was performed at 3 hours post exercise and reported to alleviate 
muscle soreness and swelling but had no effect on enhancing the recovery of muscle function after 
maximal eccentric exercise of the elbow flexors (Zainuddin, Newton, Sacco, & Nosaka, 2005). 
Similarly, Denegar and Perrin (1992) compared 5 treatment groups (8 untrained women per group) 
consisting of TENS, ice pack, a combination of TENS and ice pack, sham TENS and control in 
which the therapeutic treatment was performed 48 hours after elbow flexor exercise with a 
dumbbell. Their study showed that the combination of TENS and ice pack and the ice pack 
treatments had a significant analgesic effect, but no significant effect on recovery of muscle 
strength. Weber and colleagues (1994) compared therapeutic massage (2 min light effleurage, 5 min 
petrissage followed by 1 min effleurage), microcurrent stimulation and upper body ergometry (60 
rpm for a workload of 400 kgm/min) applied immediately and 24 hours after exercise, and reported 
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that none of the treatments had a significant effect on alleviating muscle soreness and maximal 
isometric contraction strength following dumbbell exercise of the elbow flexors until exhaustion. 
Considering the above and other studies (e.g. Allen, et al., 1999; Bonacci & Higbie, 1997; 
Tourville, Connolly, & Reed, 2006), it appears that most of the interventions tested in the previous 
studies were not strongly effective for attenuating DOMS and enhancing muscle function recovery. 
Therefore it is necessary to establish an improved therapeutic treatment for EIMD.  
 Pulsed electromagnetic field therapy (PEMFT) is an electrotherapy that uses an alternating 
current through a copper coil to produces a magnetic field that penetrates deeply through tissues and 
is believed to enhance cellular repair, reduce pain, oedema and inflammation (Markov, 2007; 
Robertson, Ward, Low, & Reed, 2006). There is significant evidence to suggest that PEMFT can 
treat non-union fractures, avascular necrosis, and alleviate pain in chronic musculoskeletal injuries 
such as osteoarthritis (Trock et al., 1993), carpal tunnel syndrome (Weintraub & Cole, 2008), and 
post operative pain following breast augmentation (Hedan & Pilla, 2008). Trock et al. (1993) used 
low frequency (less than 30 Hz) PEMFT consisting of 18 treatment sessions (30 minutes / session) 
in comparison to sham treatment (applied treatment by not energizing the magnetic coil) to treat 
patients with osteoarthritic pain, and reported that the PEMFT treatment group had significant pain 
relief from baseline measurements (up to 50% reduction on 10 cm VAS) compared with sham 
treatment group (10% reduction). An in vivo study demonstrated that PEMFT treatment augments 
angiogenesis, which can assist in the repair of injured tissue (Tepper et al., 2004). The supply of 
oxygen and nutrients via the blood vessels is known to be essential for tissue repair (Zampetaki, 
Kirton, & Xu, 2008), thus if PEMFT treatment can increase blood flow and muscle oxygenation, a 
more rapid recovery of injured tissue could follow. However, experimental studies measuring the 
changes in blood flow following PEMFT treatment are lacking. 
To the best of our knowledge only one study has investigated the effects of PEMFT on the 
signs and symptoms of muscle damage. Spodaryk (2002) had 36 healthy men perform exhaustive 
eccentric exercise of the elbow flexors using a dumbbell and then applied either 20 minutes of 
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PEMFT or sham treatment for 5 days starting from immediately post-exercise and found significant 
attenuation of muscle soreness (VAS) and smaller decreases in ROM in PEMFT treatment group 
only but no enhanced recovery of muscle strength.  
A portable low frequency PEMFT device called e-cell™ (Global Energy Medicine, Western 
Australia, see Appendix A), which has been cleared by the Australian Register of Therapeutic 
Goods, is anecdotally reported to increase blood flow and cellular proliferation, reduce 
inflammation and enhance the healing of muscle strain injuries, tendonitis and contusions. 
Furthermore, swelling that occurs with the movement of inflammatory cells and fluids to an injured 
area following strenuous unaccustomed eccentric exercise is known to contribute to the sensation of 
pain (Connolly, et al., 2003).  As a consequence, if the e-cell™ treatment was to reduce oedema, the 
associated DOMS could be eased. As mentioned earlier PEMFT treatment has been shown in vivo 
studies to stimulate cellular repair. If e-cell™ treatment is effective for regeneration of skeletal 
muscle fibres and connective tissue surrounding the fibres, it is possible that the treatment could 
enhance muscle function recovery after eccentric exercise. Therefore, it seems reasonable to assume 
that e-cell™ treatment could be effective for alleviating DOMS and enhancing recovery of losses in 
muscle function after EIMD. However, no experimental studies have yet examined the effects of e-
cell™ treatment on markers of muscle damage induced by eccentric exercise.  
 
 
1.2 Purpose 
The purposes of the present study were to investigate whether 30 minutes of e-cell™ 
treatment would effect muscle temperature, blood flow and oxygenation compared to sham 
treatment when it was applied to the elbow flexors (Study 1). To compare changes in the dependent 
variables of muscle damage of the elbow flexors seen in e-cell™ and sham treatment arms when 
applied 30 minutes, 1, 2, 3 and 4 days after eccentric exercise of the elbow flexors (Study 2).  
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1.3 Research Questions 
1) Does 30 minutes of e-cell™ treatment increase biceps brachii temperature? (Study 1) 
2) Does 30 minutes of e-cell™ treatment increase muscle oxygenation and blood flow in the 
biceps brachii? (Study 1) 
3) Does e-cell™ treatment improve MVC torque, ROM, upper arm circumference, muscle 
soreness and tenderness acutely? (Study 2) 
4) Does e-cell™ treatment influence muscle damage markers (MVC torque, ROM, upper arm 
circumference, muscle soreness, tenderness and plasma CK activity) following eccentric 
exercise of the elbow flexors, and do these differ between genders? (Study 2) 
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CHAPTER TWO 
LITERATURE REVIEW 
 
Electrotherapy Treatment of Exercise-Induced Muscle Damage 
2.1 Introduction 
Exercise-induced muscle damage (EIMD) results in symptoms such as prolonged losses of 
muscle function, increased passive stiffness, muscle soreness and swelling (Chen, et al., 2011; 
Nosaka & Clarkson, 1995; Nosaka, et al., 2002). EIMD is repairable, but could increase the risk of 
musculoskeletal injuries, and impair exercise performance and activities of daily living (Cheung, et 
al., 2003). Therefore, interventions are needed to attenuate the symptoms of EIMD.  
There are many modalities used as interventions for soft tissue injuries. These interventions 
can be classified as prophylactic or therapeutic based on the timing of their application. A 
prophylactic intervention is characterised by its application prior to an injury. Conversely, 
therapeutic interventions are typically applied once the primary damage has already occurred. 
However, many of the interventions are used both prophylactically and therapeutically. Some 
prevalent prophylactic and/or therapeutic interventions include pre-exercise isometric (Chen, Chen, 
Pearce, & Nosaka, 2012) and eccentric contractions (Nosaka, Newton, Sacco, Chapman, & 
Lavender, 2005; Nosaka, Newton, & Sacco, 2005), pre- and post-exercise concentric contractions 
(Nosaka & Clarkson, 1997; Zainuddin, Sacco, Newton, & Nosaka, 2006), stretching (Chen, et al., 
2011; Pizza, Koh, McGregor, & Brooks, 2002), nutritional supplements (Bryer & Goldfarb, 2006; 
Maxwell, Jakeman, Thomason, Leguen, & Thorpe, 1993), non-steroidal anti-inflammatory drugs 
(Baldwin, Stevenson, & Dudley, 2001; Hasson et al., 1993), cryotherapy (Howatson & Van 
Someren, 2003; Yanagisawa et al., 2003), hot cold contrast baths (Vaile, Gill, & Blazevich, 2007), 
massage therapy (Mancinelli et al., 2006; Zainuddin, et al., 2005), compression garments 
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(Jakeman, Byrne, & Eston, 2010; Kraemer et al., 2001) and electrotherapies (Bougie, 1997; 
Denegar & Perrin, 1992). 
Among these, electrotherapies are popular interventions used by medical practitioners for the 
treatment of musculoskeletal injuries in conjunction with other therapeutic interventions such as 
transcutaneous electrical nerve stimulation (TENS), microcurrent electrical neuromuscular 
stimulation (MENS), ultrasound, vibration, pulsed electromagnetic field therapy (PEMFT), light 
amplification by stimulated emission of radiation (laser) and diathermy (Brukner & Khan, 2002; 
Watson, 2008). An electrotherapy refers to any form of treatment modality that incorporates an 
electro-physical component that can be applied externally to the human body to stimulate or 
enhance physiological processes to restore normal function (Robertson, et al., 2006; Watson, 
2008). Electrotherapies can be categorised into electrical (e.g. TENS and MENS), mechanical (e.g. 
ultrasound, vibration), electromagnetic (e.g. PEMFT and laser) and thermal (diathermy) (Brukner 
& Khan, 2002; Robertson, et al., 2006).  
It has been reported that electrotherapies are effective for enhancing recovery from 
musculoskeletal injuries. For example, Trock et al., (1993) applied 30 minutes of PEMFT for 18 
sessions to treat patients with osteoarthritic pain, and reported significantly greater pain relief from 
baseline measurements in the PEMFT group (up to 50% reduction on 10 cm visual analogue scale) 
compared to sham treatment group (10% reduction). Furthermore, it was reported that 56 patients 
suffering from chronic leg ulcers received pulsating ultrasound and had a 20% greater healing rate 
than traditional bandaging treatment group (Callam, Harper, Dale, Ruckley, & Prescott, 1987). 
Similarly, the healing of other musculoskeletal conditions such as non-union bone fractures and 
calcific tendonitis were enhanced after electrotherapy treatment (Ebenbichler et al., 1998; Mollon, 
da Silva, Busse, Einhorn, & Bhandari, 2008).  
Given that electrotherapies can enhance the healing from musculoskeletal injuries, it seems 
reasonable to assume that they could also enhance the recovery from EIMD. Several studies have 
investigated the effects of electrotherapies on the treatment of symptoms associated with EIMD.  
 9 
However, he reported effects vary considerably among the types of electrotherapy employed, 
frequency of application, muscle group utilised and their overall effectiveness. This brief literature 
review aims to describe some of electrotherapies and potential mechanisms underpinning the 
effects of electrotherapies on soft tissue injuries, and to examine the potential efficacy of 
electrotherapies in the attenuation of muscle damage symptoms.   
 
2.2 Possible Mechanisms for Electrotherapies to Enhance Recovery from Muscle 
Injury 
Understanding the physiological changes during electrotherapy treatment is necessary to 
validate the efficacy of electrotherapies. To elicit a physiologically favourable response, the target 
tissues must absorb the energy emitted from the modalities. For example, dense tissues such as bone 
or tendons will elicit favourable responses to higher energy devices compared to lower energy 
devices that will benefit less dense tissues such as muscle, nerves and cell membrane activity 
(Robertson, et al., 2006). This section provides a brief summation of the theorised physiological 
mechanisms affected by electrotherapy modalities (Figure 1). 
 
2.2.1 Mechanical Therapy 
2.2.1.1 Ultrasound 
Therapeutic ultrasound is a mechanical therapy resulting from the conversion of electrical 
energy into soundwaves, employed at frequencies between 0.7 and 3.3MHz, which can penetrate 
through the epidermis and be absorbed into the target tissue (Brukner & Khan, 2002; Robertson, et 
al., 2006). Clinicians use both continuous (thermal) and pulsed (athermal) ultrasound to treat 
various musculoskeletal conditions. Continuous ultrasound involves an uninterrupted stream of 
ultrasound waves that are reported to increase muscle blood flow and tissue metabolism (Dyson, 
1987). It is traditionally employed during the remodelling phase of wound healing to improve scar 
formation (Young & Dyson, 1990). However, during the acute phase of an injury (∼the first 72 
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hours post-injurious stimuli), thermal ultrasound is not applied since it will significantly increase 
muscle temperature (2 - 4C°) and further exacerbate acute inflammation. Pulsed ultrasound 
involves a regularly alternating stream of ultrasound waves thought to stimulate cavitation and 
streaming. The soundwaves (frequencies of 0.85 – 3MHz) are believed to penetrate the skin and 
generate micron-sized bubbles in the blood or tissue fluids which are then streamed in the direction 
of the mechanical force which is thought to influence cell membrane permeability, facilitate tissue 
metabolism, diffusion of cellular metabolites and influence the sensation of pain (Brukner & Khan, 
2002; Dyson, 1987).  
 
2.2.1.2 Vibration 
Vibration therapy is also a mechanical electrotherapy often employed by clinicians at 
frequencies between 30 and 50Hz to reduce oedema and alleviate pain from acute and chronic 
musculoskeletal injuries (Broadbent et al., 2010; Lundeberg, Nordemar, & Ottoson, 1984; 
Yarnitskya, Kunin, Brik, & Sprecher, 1997). When applied to the skin of the target area, it is 
believed to modulate the afferent input from sensory units within skeletal muscle, which may 
influence the sensation of pain associated with group III and IV afferent nerve fibres (Robertson, et 
al., 2006).  
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Figure 1: Potential mechanisms leading to the recovery of soft tissue injuries by electrotherapies. 
Each electrotherapy has been categorised into groups, where M = mechanical; T = thermal; E = 
electrical; EM = electromagnetic. It is then proposed that these electrotherapies may modify 
various physiological mechanisms within the body; for example enhanced blood flow or cell 
membrane permeability, which can possibly influence factors that affect the rate of muscle 
recovery; such as muscle fibre or connective tissue repair. ↓ indicates decrease; ↑ indicates 
increase.    
 
2.2.2 Thermal Therapy 
2.2.2.1 Diathermy 
Diathermy (Shortwave and Microwave) treatment is a thermal electrotherapy that passively 
increases muscle temperature via high oscillating electromagnetic frequencies (Brukner & Khan, 
2002). Shortwave diathermy for example is typically applied at a frequency of 27.12MHz compared 
to the higher frequencies of Microwave diathermy at 434MHz, 915MHz or 2450MHz (Robertson, 
et al., 2006). Higher frequency modalities utilising 1MHz or greater are designed to enhance tissue 
heating which is believed to influence metabolic processes, enhance muscle blood flow and 
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extensibility in collagen containing tissues (Robertson, et al., 2006). Diathermy is not utilised 
immediately post-injury since it will enhance acute inflammation; however, for the treatment of 
musculoskeletal injuries, heating tissues is thought to reduce joint stiffness by increasing 
extensibility of connective and muscle tissues (Szymanski, 2001), accelerate the removal of oedema 
associated with inflammatory processes via enhanced blood and lymph flow and potentially affect 
cell membrane permeability (Brukner & Khan, 2002; Collis & Segal, 1988). 
 
2.2.3 Electrical Therapy 
2.2.3.1 Transcutaneous Electrical Nerve Stimulation 
There is evidence to suggest TENS treatment is effective for pain relief, and in clinical 
practice is often the modality of choice for pain control (Johnson, Ashton, & Thompson, 1991). 
TENS is an electrical therapy believed to modify sensory stimulation and enhance pain thresholds 
facilitating a temporary analgesic response (Robertson, et al., 2006). The frequency, intensity and 
duration of TENS modalities can have differing analgesic effects. High frequency, short pulse 
duration TENS (80 – 120 Hz; 50 µs) is believed to engage the ‘Pain Gate Control Theory’, which 
suggests that stimulating a large area of sensory nerve fibres in the muscle can inhibit afferent 
signals sent from a smaller number of sensory nerve fibres and diminish the perception of pain 
(Melzack & Wall, 1967). Conversely, low frequency, long pulse duration TENS (2 – 5 Hz; >300 
µs) is thought to activate endogenous opioid pathways that aid to inhibit the sensation of pain 
(Sluka, Deacon, Stibal, Strissel, & Terpstra, 1999).  
 
2.2.3.2 Microcurrent Electrical Neuromuscular Stimulation  
Microcurrent electrical neuromuscular stimulation (MENS) is an electrical therapy similar to 
TENS that produces extremely low intensity (100µA - 200µA) and frequency (0.3 – 300Hz) direct 
electrical currents believed to attenuate symptoms of musculoskeletal injuries such as pain, swelling 
and losses in muscle function (Allen, et al., 1999; Robertson, et al., 2006). Clinically, MENS has 
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been used in the treatment of non-union bone fractures (Bertolucci & Grey, 1995) and tissue 
healing (Brighton & Friedenberg, 1974). At a cellular level, MENS is believed to influence the 
bioelectricity involved with the transport of ions through the cell membrane in order to maintain 
membrane permeability, which can facilitate cell proliferation and protein synthesis (Cheng et al., 
1982).      
 
2.2.4 Electromagnetic Therapy  
2.2.4.1 Laser 
Low-level laser therapy has been advocated as an effective therapeutic treatment for various 
musculoskeletal conditions such as the relief of pain (Chow, Heller, & Barnsley, 2006) and 
accelerating wound healing (Gur et al., 2002). Clinically, lasers are used at two wavelengths, with 
the helium neon (HeNe) laser at 632.8nm and the gallium arsenide (GaAs) laser at 904nm (Brukner 
& Khan, 2002; Enwemeka, 2001); however, other wavelengths of 655nm (Junior et al., 2008) and 
830nm (Junior et al., 2009) have also been reported. It is proposed that the light energy absorbed by 
the target tissues can modulate intracellular processes and reduce pain, oedema, improve 
mitochondrial function and vascularisation (Brukner & Khan, 2002).  
 
2.2.4.2 Pulsed Electromagnetic Field 
Pulsed electromagnetic field therapy (PEMFT) transmits an alternating current through a 
copper coil to produce a magnetic field that penetrates deeply through tissues and is believed to 
enhance blood flow and cellular repair, reduce pain, oedema and inflammation (Robertson, et al., 
2006). PEMFT is typically applied to treat non-union fractures (Mooney, 1990; Sharrard, 1990), 
avascular necrosis (Aaron, Lennox, Bunce, & Ebert, 1989), and alleviate pain in chronic 
musculoskeletal injuries such as osteoarthritis (Trock, et al., 1993), carpal tunnel syndrome 
(Weintraub & Cole, 2008), and post operative pain following breast augmentation (Hedan & Pilla, 
2008).  
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2.3 Electrotherapy Interventions for Exercise-Induced Muscle Damage 
Many studies have investigated the effects of various interventions on EIMD, but only a 
limited number of studies have examined the effects of electrotherapies on the treatment of 
symptoms associated with EIMD. This review introduces the studies in which interventions 
categorised as electrotherapy were used for the treatment of EIMD.  The interventions include 
ultrasound and vibration therapy (both mechanical therapies), TENS and MENS (electrical 
therapies), pulsed electromagnetic field therapy, diathermy (thermal therapy) and laser therapy 
(electromagnetic therapy). 
 
2.3.1 Mechanical Therapy 
2.3.1.1 Ultrasound 
Many studies have examined the efficacy of ultrasound as an intervention for the recovery of 
EIMD, but there is limited evidence validating its effectiveness. For example, a study by Tiidus et 
al., (2002) found that 11 subjects who received 8 minutes of daily-pulsed ultrasound after 50 
maximal eccentric contractions of the elbow flexors had no significant attenuation of any indirect 
markers of muscle damage. Similar findings have also been reported in other elbow flexor studies 
(Aytar et al., 2008; Craig, Bradley, Walsh, Baxter, & Allen, 1999; Stay, Richard, Draper, 
Schulthies, & Durrant, 1998). Contrastingly, Hasson et al. (1990) found that a single 20-minute 
application of pulsed ultrasound significantly enhanced the recovery of muscle soreness and muscle 
strength of the quadriceps one-day post-EIMD. Whilst there is some evidence to suggest that 
therapeutic ultrasound can enhance the recovery of EIMD, it appears the large majority of literature 
indicates that ultrasound has little or no effect in attenuating the signs and symptoms of muscle 
damage. 
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2.3.1.2 Vibration 
With regards to the attenuation of symptoms associated with EIMD, Lau et al. (2011) found that 30-
minutes of vibration treatment for 5 consecutive days applied to 15 subjects after performing after 
60 maximal eccentric contractions of the elbow flexors was effective at attenuating muscle soreness 
and losses in ROM but did not affect the recovery of muscle strength, swelling or plasma CK 
activity. Similarly, Bakhtiary and colleagues (2007) found that 1-minute of vibration treatment 
applied to the knee flexors and extensors of 25 subjects prior to 30 minutes of downhill walking at 
4-km per hour on a 10° incline resulted in smaller increases of muscle soreness and plasma CK 
activity but no affect on muscle strength recovery. This was also in accordance with the findings 
from Ayles, Graveson-Nielsen and Gibson (2011). It appears that like TENS, vibration treatment 
can be effective in the treatment of DOMS but has little effect on other markers of EIMD. 
 
2.3.2 Thermal Therapy 
2.3.2.1 Diathermy 
In the treatment of EIMD, Diathermy is typically applied prophylactically because its application 
immediately post-exercise is contraindicated. Nosaka et al. (2004) found that 10 female subjects 
who received 10 minutes of microwave diathermy (27.12MHz, 100W) immediately after 
performing 12 maximal eccentric contractions of the elbow flexors had no significant attenuation of 
muscle damage symptoms. Conversely, Nosaka and colleagues (2007) reported that 15 males who 
received 20 minutes of microwave diathermy treatment (150 W) 18 ± 0.4 hours prior to performing 
24 maximal eccentric contractions of the elbow flexors had significant attenuation of muscle 
soreness, faster recovery of muscle strength, as well smaller decreases in range of motion compared 
to control. Thus, it appears that the muscle temperature, time duration, and time of application prior 
to EIMD may influence the effectiveness of diathermy treatment. 
 
 16 
2.3.3 Electrical Therapy 
2.3.3.1 Transcutaneous Electrical Nerve Stimulation 
A study by Denegar and Perrin (1992) compared 5 treatment groups (8 untrained women per 
group) consisting of TENS, ice pack, a combination of TENS and ice pack, sham TENS and control 
in which the therapeutic treatment was performed 48 hours after elbow flexor exercise with a 
dumbbell. They reported the combination of TENS and ice pack treatment had a significant 
analgesic effect, but no significant effect on the recovery of muscle strength and other markers. 
Conversely, Craig et al. (1996) found that low and high frequency pulsating TENS applied for 20 
minutes to 24 subjects (n=12 per group) after performing 24 maximal eccentric contractions had no 
significant effect on the recovery of muscle damage symptoms. Thus, given the aforementioned 
studies, TENS may have a small influence on the perception of pain in relation to muscle soreness, 
but it appears that TENS has little or no influence on other muscle damage markers. Given that the 
recovery of muscle function, most notably muscle strength, is perhaps the most important muscle 
damage variable (Warren, Lowe, & Armstrong, 1999), TENS appears limited as an effective 
electrotherapy for the treatment of muscle damage. 
 
2.3.3.2 Microcurrent Electrical Neuromuscular Stimulation 
Studies investigating the effects of MENS on the symptoms of EIMD appear to have 
conflicting results. Curtis and colleagues (2010) found that 20-minutes of MENS treatment 
employed at varying frequencies (18 - 191Hz) and an intensities (100 - 200µA) applied after 75 
maximal voluntary eccentric contractions of the knee flexors provided significantly less soreness 
compared to control. Conversely, Allen et al., (1999) found that 20-minutes of MENS treatment (10 
minutes at 30Hz, 200µA and 10 minutes at 0.3Hz, 100µA) had no significant effect on reducing 
pain or losses in ROM compared to sham treatment after exhaustive eccentric exercise of the elbow 
flexors using a dumbbell. In addition, Weber et al., (1994) compared between MENS, therapeutic 
massage and upper body ergometry groups with 8 minutes of the treatments applied immediately 
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after and 24 hours after maximal exhaustive eccentric contractions of the elbow flexors, and 
reported that none of the interventions had a significant effect on alleviating muscle soreness and 
maximal isometric contraction strength.  
 
2.3.4 Electromagnetic Therapy 
2.3.4.1 Laser 
Studies evaluating the effectiveness of laser therapy on muscle damage symptoms have been 
conflicting. Baroni et al., (2010) found that when 18 males (36 total) were exposed to laser therapy 
(810 nm, 200mW) for 3 minutes (30 seconds in each of 6 points of the quadriceps) and applied 24 ± 
1 hours prior to 75 maximal eccentric contractions of the knee extensors, they had significantly 
smaller increases in plasma CK activity and lactate dehydrogenase, smaller decreases and faster 
recovery of isometric strength but no change in the recovery of muscle soreness (VAS) compared to 
placebo treatment. Conversely, Craig et al., (1999) showed that 4 minutes of combined low 
intensity laser therapy/phototherapy (660-950nm, 534mW) applied after 18 males and 18 females 
performed 3 sets of maximal exhaustive eccentric contractions of the elbow flexors using a 
dumbbell had no significant attenuating effect on any signs of muscle damage compared to placebo 
and control conditions. Since the exercise and laser therapy treatment protocols were different in the 
aforementioned studies, it is difficult to make a direct comparison between the two. However, it 
appears that laser therapy can provide prophylactic effects when applied approximately one day 
prior to EIMD of the knee extensors. Given that only one study has demonstrated the efficacy of 
laser therapy, further evidence is required to determine whether this therapy is an effective 
treatment for EIMD. 
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2.3.4.2 Pulsed Electromagnetic Field 
To the best of our knowledge, only one study that has investigated the effects of PEMFT 
treatment on the signs and symptoms of muscle damage. The study by Spodaryk (2002) had 36 
healthy men perform exhaustive eccentric exercise of the elbow flexors using a dumbbell, and were 
treated for 20 minutes of PEMFT for 5 days, starting from immediately post-exercise, had 
significant attenuation of muscle soreness (VAS) and smaller decreases in ROM. However, they did 
not report on the recovery of strength or plasma CK activity. Consequently, it remains unclear as to 
whether PEMFT affects the recovery of muscle function following eccentric exercise. 
 
2.4 Conclusion 
The limited evidence suggests that the majority of electrotherapies are strongly effective for 
attenuating DOMS, enhancing the recovery of muscle function or other symptoms of EIMD. Of the 
electrotherapy studies reviewed, several found some effect on reductions in muscle soreness and 
swelling, but very few studies have found any significant effect on muscle function recovery. The 
recovery of muscle function, particularly the ability to generate force, is regarded as the most 
critical marker of muscle damage due to its impact on exercise performance and its requirement to 
complete activities of daily living. Given that the recovery of muscle strength is the most important 
marker of muscle damage, only one electrotherapy study, employing pulsed ultrasound, has 
reported a significant effect on the recovery of muscle strength following EIMD. This suggests that 
existing electrotherapies have not been particularly effective in the treatment of EIMD and a more 
effective electrotherapy must be established for the treatment of symptoms associated with EIMD. 
The electrotherapy PEMFT is believed to influence a number of physiological mechanisms 
including enhanced blood flow and cell membrane permeability and may have the greatest potential 
to enhance the healing of soft tissue injury and attenuate the symptoms associated with EIMD.  
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CHAPTER THREE 
METHODS 
 
3.1 STUDY 1 – The effects of 30 minutes of e-cell and sham treatment on muscle 
temperature, muscle blood flow and oxygenation of the biceps brachii 
 
3.1.1 Participants 
Nine healthy male volunteers (23.6 ± 3.7 years, 176.5 ± 4.5 cm, 74.6 ± 5.9 kg) were recruited 
from the staff and students of Edith Cowan University for this study following approval from the 
Human Research Ethics Committee. Participants were free from musculoskeletal injuries to the 
upper body and none were taking medication or dietary supplementation before participating. All 
participants completed an informed written consent form and a medical questionnaire prior to 
testing.   
 
3.1.2 Experimental Design 
A company (Global Energy Medicine, WA, Australia) provided two identical e-cell™ 
devices; one being the actual e-cell™ and the other a sham device that did not generate 
electromagnetic pulses. The investigator and participants were blinded to the devices (only 
informed as Device A and Device B). Participants were required to attend one testing session where 
one arm received e-cell™ treatment and the other arm received sham treatment. The treatment 
device used and the choice of arm (dominant arm versus non-dominant arm) were chosen at random 
and counterbalanced among the participants.  
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The dependant variables measured were muscle temperature, blood flow (total haemoglobin 
volume) and muscle oxygenation (tissue oxygenation index). Changes in the measures after 
treatment were compared between the e-cell™ and sham treatment.  
 
3.1.3 e-cell™  and Sham Treatments 
Each subject lay supine on a massage table and requested to keep both arms as still as 
possible until the treatment period had concluded to minimise changes in blood flow and muscle 
temperature due to movement. The devices (similar in shape and size to a computer mouse, 
powered by a rechargeable internal battery and weighing approximately 140 g) were placed 
longitudinally along the lateral aspect of the biceps brachii and held in place with adhesive tape, 
aligning the midpoint of the device with the mid-belly of the biceps brachii (Figure 2). The e-cell™ 
and sham treatments were applied for 30 min. When the devices were switched on, green and red 
lights would flash to indicate they were operating and then turned off after 30 min of treatment 
indicated by the sound of a double beep. A stopwatch was also used to ensure the 30 min treatment 
time was adhered to.  
 
 
 
Figure 2: e-cell™ and sham treatments applied to the subjects arm. 
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3.1.4 Muscle Temperature 
Changes in muscle temperature was measured by a thermometer (model N550; Nikkiso- YSI 
Co., Ltd, Tokyo Japan), with a needle thermistor probe as shown in figure 3 (model N451; Nikkiso-
YSI Co., Ltd, Tokyo Japan) inserted to a depth of 20mm, corrected for skin thickness, at a 45° 
angle into the biceps brachii, and the muscle temperature was recorded after stabilisation. The 
thermometer and thermistor was calibrated according to the manufacturers specifications before 
testing each subject. The sterilised thermistor probe (22 gauge, 70mm) was then inserted at 4 sites 
(2 measurements for each arm). The first site was standardised at 10mm laterally adjacent to the 
NIRS probe determined as one-third the distance from the lateral epicondyle of the humerous to the 
lateral aspect of the acromion process, and the second site was 5 mm above the first site. 
Measurements were taken 5 min before and 30 min (immediately after) after treatment. The 
temperature measures were counterbalanced between participants as to whether e-cell or sham arm 
was recorded first. 
 
 
 
 
Figure 3: Muscle temperature thermistor probe needle (a) and 2 insertion sites (b). 
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3.1.5 Muscle Oxygenation and Blood Flow 
Changes in muscle oxygenation and blood flow in the biceps brachii was measured using a NIRO-
200 (Hamamatsu Photonics, Japan) NIRS system (Figure 4). The NIRO-200 optical probe unit consists 
of one emitter (laser emitting diodes of 775, 810 and 850 nm) and one detector (two silicon photodiodes 
separated by a 6 mm centre-centre distance) that measures changes in oxygenated-haemoglobin (O2Hb), 
deoxygenated-haemoglobin (HHb) and the total haemoglobin volume (tHb = O2Hb + HHb). The tissue 
oxygenation index (TOI) can then be expressed as a percentage (TOI = O2Hb / tHb x 100). Thus 
changes observed in tHb can be considered as an indirect measure of changes in blood flow and changes 
in TOI reflect the percentage of O2 remaining in the bloodstream. The NIRS system was calibrated prior 
to each testing session according to the manufacturers standard procedures. The probe unit was firmly 
attached to the skin at the mid-belly of the biceps brachii with double-sided adhesive tape to ensure no 
sliding of the probe on the skin. The NIRS probe in relation to the treatment device was aligned 
adjacently with minimal direct contact between the two (less than 140 g of weight), and the midpoint of 
both was aligned with the mid-belly of the biceps brachii. The NIRO-200 system recorded TOI and tHb 
levels from 5 min prior to the onset of treatment and continued until the treatment concluded (30 min). 
Baseline measures of TOI and tHb were determined as the mean value over 1 min before the onset of 
treatment following 4 min of complete rest. TOI and tHb were also continuously recorded using the 
PowerLab (Australia) and then averaged for every 10 mins (0, 10, 20 and 30 min) and used for further 
analysis. 
 
Figure 4: NIRS probe located on the biceps brachii. 
 23 
3.1.6 Statistical Analysis 
Changes in muscle temperature from baseline to 30 min (immediately post-treatment) were 
analysed using a paired t-test and changes in TOI and tHb from baseline to 30 min (0, 10, 20 and 30 
minutes) were compared between the e-cell™ and sham treatments using a two-way repeated 
measures analysis of variance (ANOVA) using SPSS for Mac (Version 19, SPSS Corp, Chicago, 
Illinois). Data analysis was performed by a statistical significance set at P<0.05. 
 
3.2 STUDY 2 – The effects of e-cell and sham treatment on muscle damage 
symptoms 
 
3.2.1 Participants 
A total of 16 volunteers, 8 men (26.1 ± 6.1 years; 177.1 ± 7.8 cm; 80.1 ± 13.4 kg) 
and 8 women (23.4 ± 4.2 years; 170.1 ± 10.4 cm; 67.1 ± 9.6 kg), were recruited for this study. The 
sample size was calculated by the equation “N=2+C(s/d)2” where “N” is the number of participants, 
“C” is a constant that depends on values chosen for α and β (when α=0.05, β=0.8, C=7.85), “s” is 
the standard deviation of the population means and “d” is the difference to be detected. Based on 
the data from a previous study using the same eccentric exercise (Zainuddin, et al., 2006), muscle 
soreness measures are expected to be around 50 with a standard deviation of 20 (50 ± 20mm). It is 
assumed that 30% reduction in muscle soreness is physiologically significant and the e-cell™ 
treatment could result in 15mm reduction in muscle soreness over all with a power of 80% and a 
significance level of 5%. Therefore, “s” is 20 and “d” is equal to 15 for the equation. 
N = 2+C(s/d)2 = 2 + (7.85)(20/15)2 = 15.95 
Thus, 16 participants were recruited for this study, which was divided into 8 men and 8 
women. All participants completed an informed written consent form and medical questionnaire 
prior to the onset of the study. Female participants were also required to complete a menstrual 
history questionnaire. Ethical approval from the Human Research Ethics Committee was ensured 
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prior to commencing the study. The participants had not performed resistance training of the upper 
limbs for at least six months prior to the study. They did not have any current or previous injury of 
the elbow joints, elbow flexors, tendons and other tissue around the joints, had no neuromuscular 
disorders and were not taking any medications. Participants were requested not to change their 
lifestyle and diet, not to take any anti-inflammatory drugs or nutritional supplements and not to 
perform unaccustomed exercise during the experimental period.  
 
3.2.2 Experimental Design  
This was a double-blinded, randomised, crossover design study. As previously mentioned, the 
company provided two identical e-cell™ devices; one being the actual e-cell™ and another that did 
not generate electromagnetic pulses (sham). Participants performed a bout of maximal eccentric 
exercise of the elbow flexors of each arm 4 weeks apart. Female participants performed the exercise 
during the mid-follicular phase (lowest oestrogen and progesterone levels) of their menstrual cycle, 
since oestrogen may have a protective effect on skeletal muscle and may therefore reduce the 
markers of eccentric exercise-induced muscle damage (Kendall & Eston, 2002). One arm received 
e-cell™ treatments and the other arm received sham treatments on five occasions such as 30 
minutes after the exercise, and 1, 2, 3 and 4 days following the exercise. The treatment duration was 
30 minutes for each occasion, which is normally used in the e-cell™ treatment. The experiment 
period included one block of 9 days for the first bout (familiarisation session, reliability testing 
session 3 days before exercise, before and immediately after exercise, 1, 2, 3, 4, 5, and 7 days post-
exercise) and one block of 7 days of testing for the second bout (before and immediately after 
exercise, 1, 2, 3, 4, 5, and 7 days post-exercise). In the testing session, maximal voluntary isometric 
contraction (MVC) torque of the elbow flexors, range of motion (ROM) of the elbow joint, upper 
arm circumference, muscle soreness and pressure pain threshold (PPT) of the elbow flexors, and 
blood samples to assess plasma creatine kinase (CK) activity were taken. Changes in these 
measures over time were compared between the conditions. To examine the acute effects of the 
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treatment, MVC torque, ROM, upper arm circumference, muscle soreness and PPT measurements 
were taken immediately after the treatments performed 30 min, and 1, 2, 3 and 4 days post-exercise, 
and were also compared between conditions. 
 
3.2.3 Familiarisation Session 
Participants participated in a familiarisation session before they participated in the study. 
Participants were restricted to performing 2 maximal isometric contractions at 60˚ and 2 maximal 
isokinetic concentric contractions at 30˚·s− and 210˚·s− during this session on the lever arm of the 
isokinetic dynamometer (Cybex 6000, Lumex Inc. Runkonkoma, USA). No eccentric contractions 
were performed to minimise any muscle damage to the elbow flexors. However the participants 
were shown and briefed on the eccentric exercise protocol. Measurements including ROM, upper 
arm circumference, muscle soreness and PPT, and plasma CK activity were also demonstrated.  
 
3.2.4 Eccentric Exercise  
The exercise protocol consisted of 10 sets of 6 maximum voluntary eccentric contractions of 
the elbow flexors against the lever arm of the isokinetic dynamometer moving at a constant velocity 
of 30˚·s−. This protocol has been shown to induce muscle damage in previous studies (Chapman, et 
al., 2006; Chen, Nosaka, & Sacco, 2007; Saka et al., 2009). Participants were randomly chosen to 
perform the initial bout of exercise with either their dominant or non-dominant arm and they were 
individually positioned on a seated preacher arm curl bench with a supinated forearm position and 
the elbow aligned with the axis of rotation of the dynamometer. The elbow joint was forcibly 
extended from a flexed position (90˚) to a fully extended position (0˚) in 3 seconds (Figure 5). 
Participants were verbally encouraged to generate a maximal isometric force at the starting position 
and to maximally resist against the elbow extending action throughout the full range of motion. 
After each eccentric action, the isokinetic dynamometer returned the arm to the flexed position at a 
constant velocity of 9˚·s− while participants were asked to relax the arm, creating a 10 second 
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passive recovery between contractions. The rest period between sets was 3 minutes. Torque and 
displacement signals were obtained directly from the dynamometer output and captured using a data 
acquisition hardware and software system (Power Lab, Australia). Average peak torque (Nm) was 
determined as the mean peak torque for 6 eccentric contractions over 10 sets and work during 
exercise (J) was calculated as the average peak work of the 6 repetitions over 10 sets of the 
eccentric exercise bout. 
 
 
 
 
 
Figure 5: Eccentric exercise protocol. Each eccentric contraction commenced at an elbow joint of 
90° (a) and finished at 0° (b). 
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3.2.5 e-cell™  and sham Treatments  
The e-cell™ (Global Energy Medicine, Australia) was applied to a randomly assigned 
exercise arm and the other exercised arm received sham treatment (the device was applied without 
electromagnetic pulses). The order of the conditions (e-cell™, sham) as well as the arm dominance 
was counterbalanced amongst the participants. The device (similar in shape and size to a computer 
mouse, is powered by a rechargeable internal battery and weighs approximately 140 g) was placed 
longitudinally along the lateral aspect of the biceps brachii and held in place with a specially 
designed Velcro strap, aligning the midpoint of the device with the mid-belly of the biceps brachii 
(Figure 6). The Velcro strap (containing the device) was secured on the upper arm so that the 
position of the device would not alter throughout the entire treatment period, while also ensuring 
the strap was not too tight as to induce the enhanced recovery effects of compression. The subject 
was seated in a chair during the entire treatment period. The e-cell™ treatment had a pulse duration 
of 380 µs, frequency of 75 Hz with the intensity of the electromagnetic pulse set at 10 mT.  
 
 
 
Figure 6: e-cell™ and sham treatments applied to a subject and held in place with a specially 
designed Velcro strap. 
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3.2.6 Maximal Voluntary Isometric Contraction (MVC) Torque 
 MVC torque was measured on a Cybex isokinetic dynamometer with a HUMAC system 
(CSMI Medical Solutions, Massachusetts, USA) that was connected to a power lab system 
(Powerlab, ADInstruments, Castle Hill, Australia). The participants were positioned as they were 
for the eccentric exercise protocol. As shown in Figure 7, participants performed two 3-s maximal 
isometric contractions at elbow joint angles of 90˚, 60˚ and 30˚ (where 0˚ represents a fully 
extended elbow joint angle) in this order with 30 seconds rest between contractions at the same 
joint angle and 60 seconds rest between contractions at different joint angles. Participants were 
asked to generate maximal force as fast as possible when a signal was given. Verbal 
encouragements were given during all muscle strength testing. The higher torque of the two 
measures was used for further analysis.  
 
 
 
 
Figure 7: Measurements of MVC torque at 90° (a), 60° (b), and 30° (c) on the preacher arm curl 
bench and isokinetic dynamometer. 
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3.2.7 Range of Motion (ROM)  
A plastic goniometer was used to measure ROM of the elbow joint. The ROM was calculated 
as the difference between two types of joint angles; extended elbow joint angle (EANG) and flexed 
elbow joint angle (FANG) (Figure 8). The EANG was determined when the subject attempted to 
fully extend the elbow joint as much as possible in the same setting as that of RANG. The FANG 
was determined when the subject attempted to fully flex the elbow joint to touch the shoulder of the 
same side with the palm. To measure these, a semi-permanent ink pen was used to create a mark on 
the skin to achieve a consistent measurement. The landmarks where the marks were placed included 
the lateral epicondyle of the humerous, the acromion process and the mid point of the styloid 
process of the ulna and radius. Measurements were taken twice for each type of joint angle and the 
mean value of the two measurements was used for ROM by subtracting FANG from EANG. 
 
 
 
 
Figure 8: Measurements of FANG (a) and EANG (b) using a goniometer. 
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3.2.8 Upper Arm Circumference (CIR) 
A constant tension tape was used to measure the CIR of the exercise limb while the arm was 
hanging relaxed by the subject’s side. The measurements were taken from three sites, the mid-belly 
of the biceps brachii determined as half way between the lateral aspect of the acromion process and 
lateral epicondyle (Deighan, De Ste Croix, Grant, & Armstrong, 2006), and 3 cm above and below 
the mid-belly. Each site was marked with a semi-permanent ink marker to obtain consistent 
measures. Measurements were taken twice at each site with the mean of the two measurements 
being recorded. The mean measurement from the three sites were summated and averaged to 
produce a CIR measure used for further analysis.  
 
 
 
 
Figure 9: Measurements of upper arm circumference with constant tension tape. 
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3.2.9 Muscle Soreness 
The level of muscle soreness was assessed using a 100 mm visual analogue scale (VAS), in 
which 0 mm indicated no pain and 100 mm represented extreme pain. The participants were asked 
to mark their level of perceived soreness on the VAS while the corresponding joint was extended by 
the investigator with the resulting extension soreness measure used for further analysis. Palpation 
was also applied using the index and middle fingers slowly in a circular motion 5 times on three 
sites of the upper arm including the mid-belly of the biceps brachii, and 3 cm above and below the 
mid-belly. One measurement was taken from each site, which was used for further analysis. 
 
 
 
Figure 10: The investigator assessed extension soreness (a) and muscle soreness upon palpation of 
the upper arm (b) on the preacher arm curl bench. 
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3.2.10 Pressure Pain Threshold (PPT)  
PPT is a measure that corresponds with muscle tenderness. It was recorded using an 
electronic algometer (Somedic AB, Sweden) with a stimulation area of 1.0 cm. The probe head of 
the algometer was placed perpendicular to the measurement sites, which included the mid-belly of 
the biceps brachii, 3 cm above and below the mid-belly. Force was gradually applied until the 
subject reported the first feeling of noticeable pain. The PPT was performed twice with a 30-s 
interval between measures. The absolute value (in kPa) corresponding to the amount of force 
applied was noted and the mean of the two measures for each site was recorded. The recorded 
absolute value (kPa) was then converted into a percentage with pre-exercise values set at 100%.  
 
 
 
 
Figure 11: Measurements of pressure pain threshold using an electronic algometer. 
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3.2.11 Plasma CK Activity 
Blood samples were collected from the participants by making a small prick on the end of a 
finger and 30 µl of blood was loaded onto a CK test strip (Reflotron CK, Inverness Medical, 
Cheshire, UK) and measured by a Reflotron (Roche Diagnosis, Germany). If the plasma CK value 
exceeded 1500 U/L, the blood sample was diluted with saline solution.  
 
 
 
 
Figure 12: Measurement of plasma CK activity using a Reflotron. 
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3.2.12 Statistical Analysis 
Data analyses were performed by a statistical software package (SPSS version 19.0) with a 
statistical significance set at p<0.05. Intra-class correlation coefficient (ICC) and coefficient of 
variation (CV) statistics were used to calculate the test-retest reliability of all the dependent 
variables (Table 1). The comparison between male and female participants for the changes in the 
dependent variables over time (pre-, immediately post-, 60 minutes, 1-5 and 7 days post) was 
performed using a two-way repeated measures ANOVA. To analyse the acute effects, changes in 
measures before and after treatment for days 1-4 were compared between arms by a two-way 
repeated measures ANOVA. Changes in the dependent variables over time were also compared 
between arms by two-way repeated measures ANOVA. If the ANOVA showed a significant 
difference between conditions for main or interaction effect, a LSD post hoc test was applied to find 
significant differences between pairs of observations. To examine the magnitude of effect between 
exercise and treatment, an independent t-test was performed. Data are presented as means ± SEM, 
unless otherwise stated. 
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CHAPTER FOUR 
RESULTS 
 
4.1 STUDY 1  
4.1.1 Muscle Temperature 
There were no significant differences (t=2.974, df=8, p=0.324) in pre-exercise measures 
between e-cell™ (33.64 ± 0.38°C) and sham (33.97 ± 0.20°C) treatment arms. Figure 13 shows the 
changes in biceps brachii muscle temperature, which increased (p<0.05) after e-cell™ treatment 
only and was 0.55 ± 0.22°C higher (t=2.751, df=8, p=0.033) than after sham treatment.  
 
 
 
Figure 13: Changes in Biceps Brachii 
muscle temperature after 30 mins of e-
cell™ and Sham treatment. *Indicates 
significant difference (p<0.05) 
between e-cell™ and sham treatments. 
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4.1.2 Total Haemoglobin Concentration (tHb) 
The mean changes in tHb during e-cell and sham treatment are shown in Figure 14. No significant 
differences (F1,8=0.324, p=0.808) in the changes in tHb over time were evident between e-cell™ and 
sham treatments.  
 
 
 
Figure 14: Changes in total 
haemoglobin concentration at 10, 20 
and 30 mins after e-cell™ and sham 
treatment. n.s No significant 
difference was seen between 
treatment conditions. 
 
 
 
4.1.3 Tissue Oxygenation Index (TOI) 
There were no significant (F1,8=0.148, p=0.710) changes in TOI from baseline to the end of 
treatment for both conditions (Figure 15). Similarly no significant differences (F1,8=2.038, p=0.191) in 
the mean changes of TOI over time were evident between e-cell™ and sham treatments. 
 
 
 
Figure 15: Mean tissue oxygenation 
during 30 minutes of e-cell™ and 
sham treatments. 
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4.2 STUDY 2  
4.2.1 Reliability of Measurements 
Intraclass correlations (ICC) and coefficient of variation (CV) were used to assess the test-
retest reliability over the reliability and pre-exercise testing sessions for the dependant variables 
(Table 1). Muscle soreness was not determined as all participants recorded scores of zero on the 
VAS for extension and palpation soreness. Values of 0.89 – 1.0 for ICC showed substantial 
reliability of the measures. Additionally, all CV values were less than 10% indicating good 
reliability.  
 
Table 1: Test-retest reliability of dependent variables using intraclass correlation coefficient (ICC) 
and coefficient of variation (CV; 95% CI) 
Variable ICC CV 
MVC torque at 30°  0.95 4.2% 
MVC torque at 60°  0.96 4.0% 
MVC torque 90°  0.98 3.7% 
ROM 0.97 0.6% 
CIR  0.95 0.5% 
PPT  0.89 8.4% 
Plasma CK Activity  0.93 8.4% 
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4.2.2 Gender Effects  
A comparison was made for the changes in muscle damage markers, regardless of treatment 
condition, between male (n=8) and female (n=8) participants post-eccentric exercise (Table 2). This 
was done to establish whether gender specific differences existed for any of the criterion measures. 
No significant gender differences were found for the dependent variables except for upper arm PPT 
(average of 3 bicep sites), with male participants recovering to baseline values by day 5 compared 
to females that were still 9% below baseline values but had recovered by day 7. Even if there was a 
gender effect for PPT, the counterbalanced arm-to-arm experimental design allows us to combine 
the data so that a comparison can still be made between e-cell™ and sham conditions, regardless of 
gender. 
 
          Table 2: Interaction effect between Male and Female groups 
Variable Group Time Interaction 
 F value p value F value p value F value p value 
Peak Torque (Nm) 0.546 0.472 390.000 <0.000 1.639 0.110 
Total Work (Nm) 0.826 0.378 299.662 <0.000 1.748 0.084 
MVC 30°  (Nm) 0.177 0.680 67.184 <0.000 2.006 0.061 
MVC 60°  (Nm) 0.594 0.453 115.064 <0.000 2.051 0.055 
MVC 90°  (Nm) 0.165 0.691 116.473 <0.000 1.892 0.078 
ROM (degrees) 3.775 0.071 47.427 <0.000 1.727 0.099 
CIR (mm) 3.583 0.065 14.817 <0.000 1.295 0.253 
SOR-Pal (mm) 3.413 0.071 81.282 <0.000 1.605 0.122 
SOR-Ext (mm) 0.011 0.918 16.476 <0.000 0.490 0.861 
PPT (kPa) 8.615 0.005 91.940 <0.000 5.670 <0.000 
CK activity (U/L) 0.010 0.920 11.772 <0.000 0.386 0.886 
Note: No significant interaction effect exists between Male and Female participants 
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4.2.3 Baseline Values comparing between e-cell™  and sham Conditions 
There were no significant differences (p>0.05) for any of the pre-exercise values between e-
cell™ and sham treatment groups (Table 3) for MVC torque, ROM, CIR, palpation (average of 3 
sites) and extension soreness, PPT (average of 3 sites) and plasma CK activity.  
         
          Table 3: Absolute baseline values for e-cell™ and sham treatment groups 
Variable E-cell Sham F value df p value 
MVC torque at 30°  (Nm) 33.8 ± 3.9 35.3 ± 4.7 1.524 1,15 0.236 
MVC torque at 60°  (Nm) 43.5 ± 6.7 44.3 ± 8.5 0.474 1,15 0.502 
MVC torque 90°  (Nm) 51.4 ± 4.5 53.6 ± 5.2 2.478 1,15 0.136 
ROM (degrees) 136.1 ± 2.2 136.9 ± 2.9 0.218 1,15 0.668 
CIR (mm) 282.3 ± 6.4 283.6 ± 2.5 0.521 1,15 0.459 
Palpation Soreness (mm) 0.1 ± 0.1 0.1 ± 0.1 0.000 1,15 1.000 
Extension Soreness (mm) 0.1 ± 0.1 0.1 ± 0.1 0.000 1,15 1.000 
PPT (kPa) 376.4 ± 12.6 384.1 ± 16.7 0.325 1,15 0.612 
Plasma CK Activity (U/L) 121.5 ± 47.6 131.7 ± 66.0 0.243 1,15 0.629 
Note: No significant baseline differences between e-cell™ and sham treatments 
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4.2.4 Peak Torque during Exercise 
There were no significant differences (F1,15=0.093, p=0.765) for the changes in mean peak 
torque (mean of 6 contractions for each set over 10 sets) during the eccentric exercise between e-
cell™ and sham treatment arms (Figure 16). The average peak torque decreased significantly by 
approximately 40% over the 10 sets for both treatment conditions. 
 
 
Figure 16: Changes in average peak 
torque for 6 contractions over 10 sets 
for e-cell™ and sham treatment 
conditions. N.s: No significant 
difference was seen between the arms. 
 
 
 
4.2.5 Work During Exercise 
There were no significant differences (F1,15=0.543, p=0.473) in the total work completed for 
each of the ten sets of eccentric exercise between arms for both e-cell™ and sham treatment 
conditions (Figure 17). Total work completed for the first set was approximately 540 J, which then 
decreased significantly by almost 44% from the first to the final set. The total work over the 10 sets 
was 3875 ± 79.8 J and 3799 ± 75.4 J for the e-cell™ and sham treatment conditions respectively. 
 
 
Figure 17: Changes in total work for 
6 eccentric contractions over 10 sets 
for e-cell™ and sham treatment 
conditions. N.s: No significant 
difference was seen between the arms. 
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4.2.6 Acute Effects of e-cell™  and sham treatments 
Changes in criterion measures after exercise were compared between the e-cell™ and sham 
treatment to evaluate the efficacy of e-cell™ treatment. There were no significant differences 
between conditions for any of the pre-exercise criterion measures however all criterion variables 
changed significantly (p<0.05) following the eccentric exercise. There was no significant acute 
effect (p<0.05) for the time course changes (days 1 – 4) between e-cell™ and sham conditions for 
any of the dependent variables (Figures 18 – 22). 
 
4.2.6.1 MVC torque 
No significant differences (F1,15=0.059-1.692, p=0.213-0.811) were found for the changes in 
MVC torque between e-cell™ and sham treatments for days 1 to 4, and for any of the elbow joint 
angles. However, MVC torque decreased significantly (p<0.05) after the 30 minutes of treatment 
for both conditions (Figure 18). The average magnitude of decrease in strength among participants 
from pre- to post-treatment was 7.5 ± 1.0% for e-cell™ and 7.9 ± 1.3% for sham conditions.  
 
Figure 18: Changes in MVC torque at 60° before (Pre) and immediately after (Post) treatments for 
days 1 – 4 after eccentric exercise for e-cell™ and sham treatment conditions. * Indicates 
significant difference (p<0.05) between Pre and Post. 
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4.2.6.2 ROM 
There were no significant changes (F1,15=0.546, p=0.471) in ROM measures from pre- to 
post-treatment for days 1 to 4 for both treatment conditions (Figure 19). 
 
Figure 19: Changes in range of motion from before (Pre) and immediately after (Post) treatment 
for days 1 – 4 after eccentric exercise for e-cell™ and sham treatment conditions. 
 
4.2.6.3 CIR 
No significant changes (F1,15=1.911, p=0.144) in CIR were evident from pre- to post-
treatment for days 1 to 4 for both e-cell™ and sham treatments (Figure 20). 
 
Figure 20: Changes in CIR (average of 3 sites including the mid-belly of the biceps brachii, and 3 
cm above and below the mid-belly) from before (Pre) and immediately after (Post) treatment for 
days 1 – 4 after eccentric exercise for e-cell™ and sham treatment conditions. 
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4.2.6.4 Muscle Soreness 
Muscle soreness with palpation (F1,15=0.647, p=0.434) and extension (F1,15=0.148, p=0.706) 
was not changed from pre- to post-treatment for days 1 to 4 for e-cell™ and sham conditions. Figure 
21 represents the muscle soreness measures during palpation, which was similar for extension 
muscle soreness. 
 
Figure 21: Changes in palpation muscle soreness (average of 3 sites including the mid-belly of the 
biceps brachii, and 3 cm above and below the mid-belly) from before (Pre) and immediately after 
(Post) treatment for days 1 – 4 after eccentric exercise for e-cell™ and sham treatment conditions. 
4.2.6.5 PPT 
Upper arm PPT (F1,15=1.431, p=0.247) did not show any significant changes from pre- to 
post-treatment for days 1 to 4 for either e-cell™ and sham conditions. Figure 22 represents PPT of 
the upper arm (average of 3 biceps sites). 
 
Figure 22: Changes in acute upper arm PPT (average of 3 sites including the mid-belly of the 
biceps brachii, and 3 cm above and below the mid-belly) from before (Pre) and immediately after  
(Post) treatment for days 1 – 4 after eccentric exercise for e-cell™ and sham treatment conditions.  
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4.2.7 Effect of Treatments on Recovery after Eccentric Exercise 
Changes in the criterion measures post exercise were compared between e-cell™ and sham 
treatments to examine the therapeutic effect of the treatment. 
 
4.2.7.1 MVC torque 
Figure 23 shows the changes in MVC torque at 60°, and the changes at other angles were similar 
to that shown. MVC torque decreased significantly (p<0.05) immediately post-exercise by 
approximately 55% from baseline but there was no significant difference (F1,15=0.731, p=0.406) 
between conditions. However, there was a significant (F1,15=8.903, p=0.009) interaction effect between 
conditions, such that following e-cell™ treatment MVC torque had recovered to 91% of baseline 
measures compared to only 81% for sham condition after 7 days. This recovery was similar for elbow 
joint angles 30° (97% cf. 82%) and 90° (90% cf. 81%) for e-cell™ and sham treatments respectively. 
Following post-hoc tests, significant differences were found at days 2, 5 and 7 between conditions. This 
was similar for other elbow joint angles that reported significant differences between conditions on days 
5 and 7. 
 
 
Figure 23: Changes in MVC-60° 
torque at baseline (Pre), immediately 
post (0), 60 minutes post (60’) and 1 
– 5 and 7 days after eccentric 
exercise between e-cell™ and sham 
treatment conditions. * Indicates a 
significant difference between 
treatment conditions (p<0.05). 
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4.2.7.2 ROM 
Figure 24 shows the changes in ROM over 7 days. Immediately post-exercise, ROM 
decreased significantly (p<0.05) by 16% from baseline and there were no significant differences 
(F1,15=0.147, p=0.707) between conditions. However, a significant (F1,15=2.546, p=0.013) 
interaction effect was found between conditions, with a faster rate of ROM recovery seen in the e-
cell™ (97%) compared with sham (94%) treatment after 7 days. Post-hoc tests revealed a significant 
difference on day 1 between conditions.  
 
Figure 24: Changes in range of 
motion at baseline (Pre), 
immediately post (0), 60 minutes post 
(60’) and 1 – 5 and 7 days after 
eccentric exercise for e-cell™ and 
sham treatment conditions. * 
Indicates a significant difference 
between treatment conditions 
(p<0.05). 
 
 
4.2.7.3 CIR 
Figure 25 shows the changes in CIR (average of 3 sites) from baseline, which was similar for 
each of the three sites that were combined for the CIR measures. CIR increased significantly 
(p<0.05) immediately post-exercise for both conditions compared to baseline but there was no 
significant difference (F1,15=0.057, p=0.871) between conditions. However, there was a significant 
difference (F1,15=10.225, p<0.000) between conditions over 7 days, such that following sham 
treatment, CIR increased (p<0.05) from immediately post-exercise compared to e-cell™ treatment 
where there was no increase in CIR from immediately post-exercise to day 7. CIR peaked on day 5 
for both conditions with 54.1 ± 8.4% less swelling after e-cell™ (5.0 ± 0.8mm) compared to sham 
treatment (10.9 ± 1.3mm). Significant differences in CIR were seen at 60 minutes, 2 – 5 and 7 days 
post exercise between conditions following post-hoc tests.  
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Figure 25: Changes in CIR at baseline 
(Pre), immediately post (0), 60 minutes 
post (60’) and 1 – 5 and 7 days after 
eccentric exercise for e-cell™ and sham 
treatment conditions. * Indicates a 
significant difference between treatment 
conditions (p<0.05). 
 
 
 
4.2.7.4 Muscle Soreness 
Figure 26 shows the changes in palpation muscle soreness based on VAS upon palpation for 
the arm. Muscle soreness developed from 1-day post-exercise for both conditions; however, there 
was significantly (F1,15 =6.158, p=0.010) less palpation soreness of the upper arm (average of 3 
bicep sites) after e-cell™ compared to sham treatment over 7 days. For example, when soreness 
peaked on day 2 there was a 19% reduction in soreness for e-cell™ (16.8 ± 2.1mm) compared to 
sham (20.6 ± 2.0mm) condition. Significant differences were observed 2, 4 and 7 days post-exercise 
between conditions following post-hoc tests. There was no significant difference for extension (F1,15 
=2.145, p=0.165) muscle soreness between conditions.  
 
Figure 26: Changes in palpation muscle 
soreness (average of 3 sites including the 
mid-belly of the biceps brachii, and 3 cm 
above and below the mid-belly) at 
baseline (Pre), immediately post (0), 60 
minutes post (60’) and 1 – 5 and 7 days 
after eccentric exercise for e-cell™ and 
sham treatment conditions. * Indicates a 
significant difference between treatment 
conditions (p<0.05). 
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4.2.7.5 Peak Muscle Soreness 
Peak muscle soreness (Figure 27) post-exercise upon palpation of the upper arm (the average 
of the 3 bicep sites) occurred between days 1 and 3 and was 14% (t= 2.751, df=15, p=0.041) lower 
after e-cell™ (21.1 ± 2.2mm) treatment compared with sham (24.5 ± 2.1mm) treatment. 
 
Figure 27: Peak muscle soreness 
upon palpation of the upper arm 
(average of 3 sites including the mid-
belly of the biceps brachii, and 3 cm 
above and below the mid-belly) after 
eccentric exercise between e-cell™ 
and sham treatment conditions. * 
Indicates a significant difference 
between treatment conditions 
(p<0.05). 
 
 
4.2.7.6 PPT 
Muscle tenderness developed (p<0.05) at 1 day post-exercise for both conditions but there 
was no difference between treatments. However, there was a significant difference (F1,15=9.754, 
p<0.000) in upper arm PPT (average of 3 bicep sites) between e-cell™ and sham treatments (Figure 
28), with the e-cell™ treatment arm recovering to baseline values by 5 days compared to sham 
treatment which was still 10% below baseline values (p<0.05). Post hoc tests showed significant 
differences at 2 – 5 days and 7 days post-exercise between conditions. 
 
Figure 28: Normalised changes in 
PPT of the upper arm (average of 3 
sites including the mid-belly of the 
biceps brachii, and 3 cm above and 
below the mid-belly) at baseline 
(Pre), immediately post (0), 60 
minutes post (60’) and 1 – 5 and 7 
days after eccentric exercise between 
e-cell™ and sham treatment 
conditions. * Indicates a significant 
difference between treatment 
conditions (p<0.05). 
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4.2.7.7 Plasma CK Activity 
Plasma CK activity was significantly higher after day 3 in both conditions; however, there 
was significantly lower (F1,15=4.080, p=0.010) increases in plasma CK activity for e-cell™ 
compared to sham treatment over 7 days (Figure 29). For example when plasma CK activity peaked 
on day 5, there was a 49% reduction after e-cell™ (1316.9 ± 536.5mm) compared to sham treatment 
(2576.2 ± 681.5mm). Based on post-hoc tests, there were significant differences on days 5 and 7 
post-exercise between conditions. 
 
Figure 29: Changes in plasma CK 
activity at baseline (Pre), 
immediately Post (0), 60 minutes 
post (60’) and 1 – 5 and 7 days 
after eccentric exercise between e-
cell™ and sham treatment 
conditions. * Indicates a significant 
difference between treatment 
conditions (p<0.05). 
 
 
 
4.2.7.8 Peak Plasma CK Activity 
Peak plasma CK activity (Figure 30) post-exercise occurred between days 4 and 5 and was 
43% (t=3.852, df=15, p=0.035) lower after e-cell™ (1504 ± 542IU/L) treatment compared with 
sham (2629 ± 742IU/L) treatment. 
 
 
Figure 30: Peak plasma CK activity after 
eccentric exercise between e-cell™ and 
sham treatment conditions. * Indicates a 
significant difference between treatment 
conditions (p<0.05). 
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4.2.8 Effects of a Contralateral Repeated Bout of Eccentric Exercise 
A comparison was made for the changes in muscle damage markers, regardless of gender or 
treatment condition, between the first and second bouts of eccentric exercise when the second bout 
was performed on the contralateral arm 4 weeks apart.  
 
4.2.8.1 Pre Exercise Values between the First and Second Bouts of Eccentric Exercise  
There were no significant differences in the pre exercise absolute values for any of the 
criterion measures between the first and second bouts of eccentric exercise (Table 4). 
 Table 4: Absolute baseline values for bout 1 and bout 2 groups 
Variable Bout 1 Bout 2 F value df p value 
MVC torque at 30°  (Nm) 35.2 ± 4.6 33.0 ± 4.0 2.761 1,15 0.117 
MVC torque at 60°  (Nm) 44.9 ± 4.5 43.1 ± 4.4 2.729 1,15 0.119 
MVC torque at 90°  (Nm) 53.0 ± 4.9 51.4 ± 4.5 2.317 1,15 0.149 
Range of Motion (degree) 136.6 ± 2.2 136.3 ± 2.1 0.027 1,15 0.877 
Upper Arm Circumference (mm) 283.1 ± 6.1 283.5 ± 2.5 0.078 1,15 0.789 
Palpation Soreness (mm) 0.1 ± 0.1 0.1 ± 0.1 0.000 1,15 1.000 
Extension Soreness (mm) 0.1 ± 0.1 0.1 ± 0.1 0.000 1,15 1.000 
Pressure Pain Threshold (kPa) 378.5 ± 12.2 386.8 ± 14.7 0.010 1,15 0.921 
Plasma CK Activity (IU/L) 119.2 ± 11.8 134.0 ± 16.4 0.517 1,15 0.483 
Note: No significant baseline differences exist between first and second bouts of eccentric 
exercise (p>0.05)
 50 
4.2.8.2 MVC torque 
Figure 31 shows the changes in MVC torque at 60°, and the changes at other angles were 
similar. MVC torque decreased significantly (p<0.05) immediately post-exercise by approximately 
55% from baseline but there was no significant difference (F1,15=0.297, p=0.594) between bouts. 
However, recovery of MVC torque was significantly different (F1,15=16.159, p<0.000) between first 
and second bouts such that 7 days following the second bout, MVC torque had recovered to 94% of 
baseline but the recovery was only 79% for the first bout. This was a similar case for elbow joint 
angles at 30° (98% and 80%) and 90° (91% and 80%) between second and first bouts respectively. 
Following post-hoc tests, significant differences were found on days 2 – 5 and 7 days post-exercise 
between bouts. Interestingly, the magnitude of difference for the recovery of MVC torque between 
first and second bouts after 7 days was 5% greater than the magnitude of difference between e-
cell™ and sham treatment.  
 
 
Figure 31: Comparison between the first 
(Bout 1) and second (Bout 2) bouts for 
the changes in MVC-60° torque at 
baseline (Pre), immediately post (0), 60 
minutes post (60’) and 1 – 5 and 7 days 
after eccentric exercise. * Indicates a 
significant difference between bouts 
(p<0.05). 
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4.2.8.3 ROM 
Figure 32 shows the changes in ROM over 7 days. Immediately post-exercise ROM decreased 
significantly (p<0.05) by 16% from baseline but there was no significant difference (F1,15=1.433 
p=0.250) in ROM measures between bouts. There was significantly (F1,15=5.144, p<0.000) faster 
recovery of ROM seen in the second bout (97%) compared to the first bout (93%) after 7 days. 
Post-hoc tests revealed significant differences on days 1 – 5 between bouts. Similarly, the 
magnitude of difference in the recovery of ROM between first and second bouts was only 1% 
greater than the magnitude of difference between and e-cell™ and sham treatment. 
 
Figure 32: Comparison between the 
first (Bout 1) and second (Bout 2) 
bouts for the changes in range of 
motion at baseline (Pre), immediately 
post (0), 60 minutes post (60’) and 1 
– 5 and 7 days after eccentric 
exercise. * Indicates a significant 
difference between bouts (p<0.05). 
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4.2.8.4 CIR 
Figure 33 shows the changes in CIR (average of 3 sites), which was similar for all circumference 
measures. CIR increased (p<0.05) immediately post-exercise for both bouts compared to baseline; but 
there was no significant difference (F1,15=0.066, p=0.799) between bouts. However, there was a 
significant difference (F1,15=15.201, p<0.000) between bouts over 7 days, such that following the first 
bout of exercise, CIR increased (p<0.05) from day 1 post-exercise compared to the second bout of 
exercise where there was no significant increase in CIR from immediately post-exercise to day 7. CIR 
peaked on day 5 for both bouts with 60% less swelling after the second bout (4.6 ± 0.7mm) compared to 
the first bout (11.3 ± 1.2mm). Significant differences in CIR were seen at 60 minutes, 1 – 5 days and 7 
days post-exercise between bouts following post-hoc tests. Interestingly, the magnitude of difference in 
CIR on day 5 post-exercise between the first and second bouts was 6% greater than the magnitude of 
difference on day 5 between e-cell™ and sham treatment.  
 
Figure 33: Comparison between the 
first (Bout 1) and second (Bout 2) 
bouts for the changes in CIR at 
baseline (Pre), immediately post (0), 
60 minutes post (60’) and 1 – 5 and 7 
days after eccentric exercise. * 
Indicates a significant difference 
between bouts (p<0.05). 
 
 
 
4.2.8.5 Muscle Soreness 
Figure 34 shows the changes in palpation muscle soreness based on VAS upon palpation for 
the arm. Muscle soreness developed from day 1 post-exercise for both bouts; however, there was 
significantly (F1,15=9.108, p<0.000) less palpation soreness of the upper arm (average of 3 bicep 
sites) after the second bout compared to the first. For example when soreness peaked on day 2, there 
was a 26% reduction in soreness after the second bout (15.9 ± 1.9mm) compared to the first bout 
(21.4 ± 2.1mm). Significant differences were found 2 – 5 days post-exercise following post-hoc 
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tests. Comparatively, the magnitude of difference for soreness of the upper arm on day 2 between 
the first and second bouts of exercise was 7% greater than the magnitude of difference between e-
cell™ and sham treatment. A significant difference (F1,15=4.433, p<0.000) was also found for 
extension muscle soreness between bouts. 
 
Figure 34: Comparison between the 
first (Bout 1) and second (Bout 2) bouts 
for the changes in palpation muscle 
soreness (average of 3 sites including 
the mid-belly of the biceps brachii, and 
3 cm above and below the mid-belly) at 
baseline (Pre), immediately post (0), 60 
minutes post (60’) and 1 – 5 and 7 days 
after eccentric exercise. * Indicates a 
significant difference between bouts 
(p<0.05). 
 
 
 
4.2.8.6 Peak Muscle Soreness 
Peak muscle soreness (Figure 35) post-exercise upon palpation of the upper arm (the average 
of the 3 bicep sites) occurred between days 1 and 3 and was 33% lower (F1,15=5.348, p<0.000) after 
the second bout (18.3 ± 2.0mm) compared with the first (27.2 ± 2.2mm). Additionally, the 
magnitude of difference for peak soreness upon palpation between the first and second bouts was 
19% greater than the magnitude of difference between e-cell™ and sham treatment. 
 
Figure 35: Comparison between the first 
(Bout 1) and second (Bout 2) bouts for peak 
muscle soreness upon palpation of the upper 
arm (average of 3 sites including the mid-
belly of the biceps brachii, and 3 cm above 
and below the mid-belly) after eccentric 
exercise. * Indicates a significant difference 
between bouts (p<0.05). 
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4.2.8.7 PPT 
Muscle tenderness developed (p<0.05) at 1 day post-exercise for both conditions and there 
was a significant difference (F1,15=11.023 p<0.000) between bouts. Additionally, there was a 
significant difference (F1,15=16.891, p<0.000) in upper arm PPT (average of 3 bicep sites) between 
bouts (Figure 36), with the second bout recovering to baseline values by day 5 compared to sham 
treatment that was still 13% below baseline values and still had not recovered by day 7. Post hoc 
tests revealed significant differences at 60 minutes, 1 – 5 and 7 days post-exercise between bouts. 
Similarly, the magnitude of difference for the recovery of muscle tenderness between the first and 
second bouts was 3% greater than the magnitude of difference between e-cell™ and sham treatment.  
 
Figure 36: Comparison between the 
first (Bout 1) and second (Bout 2) 
bouts for the normalised changes in 
PPT of the upper arm (average of 3 
sites including the mid-belly of the 
biceps brachii, and 3 cm above and 
below the mid-belly) at baseline 
(Pre), immediately post (0), 60 
minutes post (60’) and 1 – 5 and 7 
days after eccentric exercise. * 
Indicates a significant difference 
between bouts (p<0.05). 
 
 
4.2.8.8 Plasma CK Activity 
Plasma CK activity was significantly higher after day 2 for the first bout and day 3 for the 
second bout. In addition there was significantly (F1,15=8.995, p=0.009) lower increases in plasma 
CK activity for the second bout compared to the first (Figure 37). For example when plasma CK 
activity peaked on day 5, there was a 56% reduction after the second bout (1123.5 ± 416.2mm) 
compared to the first bout (2547.5 ± 725.8mm). Based on post-hoc tests, there were significant 
differences on days 3 – 5 and 7 days post-exercise between conditions. Comparatively, the 
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magnitude of difference on day 5 for plasma CK activity between the first and second bouts was 7% 
greater than the magnitude of difference between e-cell™ and sham treatment.  
 
Figure 37: Comparison between the first 
(Bout 1) and second (Bout 2) bouts for the 
changes in plasma CK activity at baseline 
(Pre), immediately Post (0), 60 minutes post 
(60’) and 1 – 5 and 7 days after eccentric 
exercise. * Indicates a significant difference 
between bouts (p<0.05). 
 
 
 
4.2.8.9 Peak Plasma CK Activity 
Peak plasma CK activity (Figure 38) post exercise occurred between days 4 and 5 and was 
50% lower (t=6.405, df=15, p=0.010) after the second bout (1386.2 ± 470.3IU/L) compared to the 
first bout (2748.3 ± 777.1IU/L). Additionally, the magnitude of difference for peak plasma CK 
activity between the first and second bouts was 7% greater than the magnitude of difference 
between e-cell and sham treatment. 
 
Figure 38: Comparison between the first (Bout 
1) and second (Bout 2) bouts for peak plasma 
CK activity after eccentric exercise between 
bouts. * Indicates a significant difference 
between bouts (p<0.05). 
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4.2.8 Comparison between the Effect of Treatment and Repeated Bout Effect 
Our previous analysis showed that both e-cell™ treatment and the contralateral repeated bout 
effect enhanced the rate of recovery from muscle damage compared to sham treatment and the first bout 
of eccentric exercise respectively. Therefore, a comparison was made to examine whether e-cell™ 
treatment or the contralateral repeated bout effect was more effective at enhancing recovery from 
EIMD. To examine the magnitude of effect between e-cell™ treatment and the contralateral repeated 
bout effect, normalised changes in MVC torque, ROM and PPT from baseline (pre: 100%) and absolute 
changes in CIR, SOR and plasma CK activity were used. In Figure 39, peak SOR and plasma CK 
activity as well as day 5 measures for MVC torque, ROM, CIR and PPT were used to calculate the 
magnitude of difference between conditions and exercise bouts for the dependent variables. Compared 
with the magnitude of change after the treatment, the second bout of exercise resulted in significantly 
faster recovery of MVC torque (p=0.030) and ROM (p=0.041), and smaller increases in SOR (p<0.000) 
and PPT (p=0.047). However, no significant difference was seen for CIR (p=0.107) and plasma CK 
activity (p=0.083). 
 
Figure 39: Comparison of the magnitude of recovery between the first and second eccentric 
exercise bouts and e-cell™ and sham treatment conditions for MVC torque, range of motion, upper 
arm circumference and pressure pain threshold on day 5 after eccentric exercise, peak soreness 
and CK activity after eccentric exercise. RBE = contralateral repeated bout effect. * Indicates a 
significant difference between treatment and exercise (p<0.05). 
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4.2.9 Comparison between the First and Second Bouts of Eccentric Exercise for the e-cell™  
Treatment Effect  
To examine the magnitude of effect between e-cell™ and sham treatments after the first and 
second bouts of exercise, normalised changes in MVC torque, ROM and PPT from baseline (pre: 
100%) and absolute changes in CIR, SOR and plasma CK activity were used. In Figure 40, peak 
SOR and plasma CK activity as well as day 5 measures for MVC torque, ROM, CIR and PPT were 
used to calculate the magnitude of effect between conditions for the dependent variables. 
Comparatively, the e-cell™ treatment was less effective after the second bout of exercise for the 
recovery of MVC torque (12%), ROM (5%), CIR (25%), SOR (14%), PPT (6%) and plasma CK 
activity (29%) compared to the first bout because of the contralateral repeated bout effect. 
 
Figure 40: Comparison of the mean magnitude of recovery between e-cell™ and sham treatment in 
the first and second eccentric exercise bouts for peak SOR and CK activity; and MVC torque, ROM, 
CIR and PPT on day 5 after eccentric exercise. 
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CHAPTER FIVE 
DISCUSSION  
 
 
The purposes of this thesis were to investigate: the influence of 30 minutes e-cell™ treatment 
on muscle temperature, blood flow and oxygenation when it was applied to the elbow flexors 
compared to sham treatment (Study 1); the acute, overall, and gender effects of 30 minutes e-cell™ 
treatment, applied over 5 consecutive days after eccentric exercise of the elbow flexors, on the 
associated symptoms and markers of eccentric exercise-induced muscle damage in comparison to 
sham treatment (Study 2).  
In relation to the research questions, the Study 1 results showed that: 1) e-cell™ treatment 
increased muscle temperature by ∼0.5°C compared to sham treatment; 2) however, no significant 
differences in muscle blood flow and oxygenation were evident between conditions. In addition, 
Study 2 results included: 3) no significant acute changes in the dependent variables from pre- to 
post-treatment for either e-cell™ and sham conditions except for an ∼8% decrease in MVC torque 
after both conditions; 4) no significant differences between genders for any of the dependent 
variables except for a significantly faster recovery of PPT scores for men than women; and when 
compared with the sham treatment, the recovery of MVC torque and ROM was significantly faster, 
with swelling, peak muscle soreness and peak plasma CK activity also significantly smaller for e-
cell™ condition. Interestingly, after further analysis, when comparing the first and second bouts 
regardless of the treatment condition, the changes in all dependent variables were significantly 
attenuated after the second bout than the first bout, and the difference in the magnitude between 
bouts was greater than the differences between the treatment conditions. This chapter will discuss 
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the main results shown above separately, the potential action of the device, and integrate the 
findings to conclude the project. 
 
5.1 Study 1 
To the best of my knowledge, no previous studies have investigated the effects of low 
frequency PEMFT on muscle temperature, muscle blood flow or oxygenation of the elbow flexors. 
Any heat produced in the target muscle after low frequency (5 – 100Hz) PEMFT was thought to 
dissipate through the circulating blood (Adey, 1993). However, the present study found that e-cell™ 
treatment increased muscle temperature by ∼0.5°C (∼1.5% increase), but sham treatment did not. 
Given that the devices were applied at the same time and under the same conditions, it is reasonable 
to assume that the temperature increase was caused by the e-cell™ treatment. Despite this, the 
magnitude of muscle temperature increase observed in the present study was much less than that 
reported in studies using higher frequency (27.12 - 2450MHz) devices such as diathermy 
(shortwave and microwave) treatment. For example, microwave diathermy studies have reported a 
∼3°C muscle temperature increase of the biceps brachii after 10 minutes of treatment (Nosaka, et 
al., 2004) and a ∼7°C increase following 20 minutes of treatment (Nosaka, et al., 2007). It is unclear 
how the PEMFT treatment increased muscle temperature but some speculation is possible. Higher 
frequency electromagnetic devices (>1MHz) are known to generate electromagnetic fields that 
stimulate a flow of current in tissues, accelerating the charged ions, which collide with adjacent 
molecules producing energy and increasing collisions which leads to heating (Robertson et al., 
2006). Thus, it is possible that the lower frequency device used in the present study was able to 
replicate similar heating effects but to a lesser extent. 
The physiological importance of the temperature increase in the present study is questionable 
given thermal therapies, believed to promote healing, require much greater increases in muscle 
temperature to enhance blood flow (Giombini, Di Cesare, Safran, Ciatti, & Maffulli, 2006). 
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Therefore, despite the temperature increase after 30-minutes of e-cell™ treatment, there is no 
evidence to suggest that such a small passively induced muscle temperature increase is 
physiologically meaningful.  
Advocates of PEMFT treatment suggest that it can effectively treat soft tissue injuries by 
increasing muscle blood flow (Markov, 2007), believing that increased blood flow can promote the 
healing of damaged tissues like those affected by muscle damage. However, there are no 
documented reports of increased muscle blood flow to passive muscle when low frequency PEMFT 
treatment is applied. The mechanism by which PEMFT is believed to influence blood flow is 
relatively unknown but it is speculated that nitric oxide maybe the molecule responsible for 
vasodilation following PEMFT exposure (Kavaliers, Choleris, Prato & Ossenkopp, 1998). In the 
present study near infrared spectroscopy (NIRS) was employed to determine changes in muscle 
oxygenation and blood flow. It was found that 30-minutes of e-cell™ treatment had no effect on 
muscle blood flow or oxygenation compared to sham treatment. However, it should be noted that e-
cell™ treatment was applied to healthy individuals with the target tissue (biceps brachii) 
undamaged. Proponents of low frequency PEMFT would argue that enhanced muscle blood flow 
could only occur if the PEMFT device was applied to injured tissue. However, pilot data using two 
men who were of similar characteristics to those used in the present study measured changes in 
muscle blood flow and oxygenation of the elbow flexors in the non-dominant arm using NIRS 
during the 30 minutes of e-cell™ treatment applied at 30 minutes, and 1 – 4 days after the same 
eccentric exercise used in the present study, also showed no increase in muscle blood flow and 
oxygenation.  
Therefore, it was concluded that e-cell™ treatment induced a small increase in muscle 
temperature but had no effect on muscle blood flow or oxygenation. Despite the lack of changes in 
muscle blood flow and oxygenation, it does not necessarily mean that e-cell™ treatment can not 
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enhance the healing of injured tissue, because there are other potential physiological mechanisms of 
PEMFT, suggested in Figure 1, that were not been tested for in the present study.  
 
5.2 Study 2 
5.2.1 Exercise 
To investigate the efficacy of interventions, arm-to-arm comparison models are often used 
(Nosaka, et al., 2007; Nosaka, et al., 2004; Zainuddin, et al., 2006). The present study used an arm-
to-arm comparison design in preference to a between-subjects design. The arm-to-arm comparison 
model was thought to be advantageous, because only one group of participants were required thus 
the total number of participants was reduced, and the within-subjects design allows for reduced 
variability in response to exercise created by heterogeneous participants (Newton, Sacco, Chapman, 
& Nosaka, 2013). Indeed, there were no significant differences in the dependent variables at pre- 
and immediately post-exercise when arm dominance, treatment and bout order were 
counterbalanced. 
The eccentric exercise protocol used in this study was effective for inducing significant losses 
in strength and ROM, increases in swelling, tenderness and plasma CK activity as well as moderate 
increases in muscle soreness. The changes in the dependent variables after maximal eccentric 
exercise of the elbow flexors such as the immediate losses in MVC torque (∼55% of pre-exercise 
measures) were equivalent to those of the previous studies in which a similar exercise protocol was 
used (Newton, et al., 2008; Nosaka, et al., 2007; Zainuddin, et al., 2006). Thus, the exercise 
protocol induced sufficient muscle damage to validate the efficacy of e-cell™ treatment.  
 
5.2.2 Reliability of Measurements 
For the test-retest reliability of the dependent variables (Table 1), the ICC measures were in 
the 0.81 – 1.0 range indicating good reliability (Landis & Koch, 1977). In addition, the CV values 
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were less than 10% for all variables indicating good reliability that allows for the detection of a 
possible treatment effect. No significant differences in pre-exercise measures were evident for any 
dependent variables, and the exercise protocols were performed similarly between the e-cell™ and 
sham treatment groups as indicated by the similar average peak torque (Figure 16) production and 
overall work performed during exercise (Figure 17). Similarly, there were no significant differences 
in any dependent variables immediately after exercise between e-cell™ and sham conditions. Thus, 
the eccentric exercise appeared to induce similar magnitude of muscle damage to both arms. 
Therefore, it is reasonable to assume that if there are any differences in the dependent variables 
between e-cell™ and sham conditions occurring after 60 minutes post-exercise, the changes can be 
attributed to the effects of the treatment, given the primary treatment was applied 30 minutes post-
exercise. Lastly, when comparing between the first and second bouts of exercise, there were no 
significant differences in pre- and immediately post-exercise measures for any of the dependent 
variables.  
 
5.2.3 Gender Effect 
In the present study, no gender differences were found for the changes in muscle damage 
markers following maximal eccentric exercise of the elbow flexors except for PPT (Table 2), where 
a significantly faster recovery was seen for men than women, but the magnitude of difference was 
small. Similar findings have been reported in a previous study where females expressed 
significantly higher sensitivity and lower thresholds to PPT compared to males (Chesterton, Barlas, 
Foster, Baxter, & Wright, 2003). As suggested previously in the methods section of this thesis, 
females with high levels of oestrogen can experience attenuated symptoms from muscle damaging 
exercise (Kendall & Eston, 2002). The mechanism of this protective effect is not fully understood 
but it is believed that elevated levels of oestrogen have antioxidant properties facilitating cell 
membrane stability attenuating the magnitude of muscle damage (Carter, Dobridge, and Hackney, 
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2001). In the present study, when comparing the effect of e-cell™ and sham treatments for each 
gender group separately, essentially the results were the same as those based on both groups 
combined. Consequently, the comparisons between the e-cell™ and sham treatments shown below 
were made for all participants.    
The lack of gender differences found in the present study is in accordance with previous 
gender studies (Rinard, et al., 2000; Sayers & Clarkson, 2001), but these studies did not measure 
PPT. Despite the lack of gender differences seen in the present study, there is conflicting evidence 
in the literature with some studies reporting that gender differences exist for the changes in muscle 
damage markers particularly with regards to losses in MVC torque and smaller increases in plasma 
CK activity (Stupka et al., 2000). For example, Seawright et al. (2008) compared the muscle 
damage markers between 58 women and 42 men after 50 maximal eccentric contractions of the 
elbow flexors and reported that women showed greater relative MVC torque losses than men 
immediately after exercise, but men had significantly higher peak CK activity than women. This 
was contrary to our findings where we found no significant MVC torque losses between genders 
immediately post-exercise and additionally, no gender differences in plasma CK activity. 
Furthermore, despite the previous findings from Seawright et al. (2008), our results revealed that 
females exhibited greater increases in plasma CK activity than men, although this was not 
significantly different. A study by Carter, Dobridge, and Hackney (2001), found that females with 
high levels of oestrogen had significantly smaller increases in plasma CK activity 72 hours 
following a 30 minute downhill running eccentric exercise protocol compared to low estrogen level 
females. In the present study, females were deliberately tested during the mid-follicular phase of 
their menstrual cycle (when oestrogen levels were low) to minimise any protective effect caused by 
high levels of oestrogen. Thus, controlling of the menstrual cycle at the beginning of the exercise 
bouts may have blunted any gender differences that may have otherwise been seen. Despite the 
conflicting previous research, the results of the present study suggest that when the menstrual cycle 
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is controlled for, gender had little effect on changes in the indirect markers of muscle damage after 
the maximal eccentric exercise of the elbow flexors. 
 
5.2.4 Acute Effect 
The acute effect was based on the measures taken before and immediately after e-cell™ and 
sham treatments. No significant changes in the dependent variables except MVC torque were found 
before and immediately after either treatment performed 1-4 days after eccentric exercise (Figures 
18 - 22). MVC torque decreased significantly around 8% immediately after both treatments (Figure 
18). In the present study, the decreases seen in MVC torque were most likely related to factors 
associated with a relaxation effect because the subjects were required to remain still and seated for 
the entire 30 minute treatment duration, which may have led to a reduced efficiency of excitation-
contraction coupling, decreased central motor drive and motor neuron excitability, or a combination 
of all three (Gandevia, 2001).  
It is unclear why no acute effect of e-cell™ treatment was seen, particularly as an overall 
effect was evident. Given that PEMFT is reported to reduce pain and inflammation in 
musculoskeletal injuries (Hedan & Pilla, 2008; Trock, et al., 1993), acute changes in muscle 
soreness, tenderness and swelling after e-cell™ treatment may have been expected. It has been 
previously suggested that PEMFT can enhance muscle blood flow (Markov, 2007), which can 
increase venous drainage and reduce swelling. However, the present study was unable to detect any 
significant change in blood flow from Study 1, and subsequently no acute effect on upper arm 
circumference or other markers of muscle damage. Nevertheless, it might be that the beneficial 
effects of the treatment could take effect sometime within the 24-hour period between treatment 
applications. Therefore, it is possible that the effect of e-cell™ treatment could have been observed 
in the hours after the 30 minutes of application in a similar manner to cold-water immersion where 
the benefits of the cooling effect occur in the hours after the treatment has ceased (Pournot, 
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Bieuzen, Duffield, Lepretre, Cozzolino & Hausswirth, 2011). However, the exact mechanism is 
unknown and any future studies investigating the effects of e-cell™ treatment would be advised to 
monitor the subsequent hours after the treatment application.  
 
5.2.5 Effect of PEMFT on recovery from muscle damage 
There were no acute effects of e-cell™ treatment on the changes in most of the dependent 
variables but interestingly, there was a significantly faster rate of recovery after e-cell™ treatment 
for all of the dependent variables except for extension soreness after maximal eccentric exercise 
compared to sham treatment (Figures 23 - 30). The recovery of MVC torque is perhaps the most 
important marker of muscle damage, since it affects exercise performance and activities of daily 
living. To the best of my knowledge, no previous studies have found any enhanced recovery of 
MVC torque after the use of a therapeutic electrotherapy treatment, although some of them reported 
significant effects on other variables such as muscle soreness and plasma CK activity (Bakhtiary, et 
al., 2007; Lau & Nosaka, 2011; Zainuddin, et al., 2005). The present study showed a significantly 
faster rate of recovery (10.3 ± 5.0%) for MVC torque after e-cell™ compared to sham treatment at 7 
days post-exercise, but MVC torque did not fully recover to baseline measures (Figure 23). Post-
hoc tests revealed significant differences were present on 2, 5 and 7 days post-exercise. Thus, it 
appears the physiologically beneficial effects of e-cell™ treatment for MVC torque recovery were 
not immediate and took time to develop. This is in accordance with the lack of acute response seen 
for e-cell™ treatment reported previously in the present study for days 1 – 4 post-exercise (Figure 
18). The present study was the first to show a more rapid recovery of MVC torque of the elbow 
flexors after eccentric exercise following the application of low frequency PEMFT. It is difficult to 
compare the results of the present study with other electrotherapy studies treating muscle damage, 
because there are differences in the type and magnitude of muscle damaged, and the mode, duration 
and the applied time of the electrotherapies. It is unclear from the present study whether longer 
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treatment duration would generate a similar or greater magnitude of MVC torque recovery. Further 
studies are necessary to investigate whether modifications to treatment duration and parameters 
would generate a more rapid MVC torque recovery.   
In terms of muscle function, it should be noted that not only MVC torque but also the 
recovery of ROM of the elbow joint was enhanced by e-cell™ treatment. There were significantly 
smaller decreases in elbow joint ROM for e-cell™ treatment compared to sham treatment (Figure 
24). Similarly, Spodaryk (2002) observed significantly smaller decreases in ROM on 2 days after 
applying a low frequency PEMFT device for 20 minutes over 5 days after exhaustive eccentric 
dumbbell exercise of the elbow flexors compared to sham and control groups. Even though e-cell™ 
treatment enhanced the rate of recovery of the elbow joint ROM, the magnitude of difference 
between e-cell™ and sham treatment in the present study appears less significant than other 
electrotherapies. Previous studies using microwave (Nosaka, et al., 2007) and vibration (Lau & 
Nosaka, 2011) therapy also reported improved recovery in elbow joint ROM, but the magnitude of 
effect in these studies appears to be greater than that observed in the present study. For example, 
Nosaka et al. (2007) and Lau et al. (2011) found significant differences between their respective 
electrotherapies and control condition after EIMD on days 1 - 4 and 3 - 7 respectively compared to 
only day 1 seen in the present study. Thus, it appears that low frequency PEMFT may not greatly 
enhance elbow joint ROM compared to other thermal and mechanical electrotherapies. It is unlikely 
e-cell™ treatment had any influence on joint stiffness (EANG) given the relatively small muscle 
temperature increase found in Study 1. Spodaryk (2002) proposed that PEMFT treatment retarded 
the perception of pain allowing for greater extension in elbow joint ROM; although in the present 
study, this did not appear possible since there was no difference in soreness measures between 
treatment conditions on day 1 after exercise. All things considered, despite the statistically 
significant differences found for elbow joint ROM in the present study between conditions, it 
appears the effect of e-cell™ treatment was not as clinically significant as other electrotherapies. 
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Swelling transpires within the muscle immediately after maximal eccentric exercise-induced 
muscle damage of the elbow flexors and typically peaks around five days post-exercise (Nosaka & 
Clarkson, 1996), which was confirmed in the present study. The amount of swelling induced post-
exercise in this study was similar to that of previous studies (Chen et al., 2012; Zainuddin et al., 
2006). In the present study there was significantly less swelling 60 minutes and 2 – 5 and 7 days 
post-exercise after e-cell™ compared to sham treatment; and furthermore, significantly less (47.4 ± 
8.4%) peak swelling was observed on day 5 after e-cell™ treatment compared to sham (Figure 25). 
Interestingly, after the first 30 minute application of e-cell™ treatment there was significantly less 
swelling (60 minutes post-exercise) compared to sham treatment, suggesting that low frequency 
PEMFT may suppress oedema that occurs during the early stages of secondary damage, which has 
been shown in a previous animal study (Lee, Maffulli, Li, & Chan, 1997). This is further supported 
by studies that have shown PEMFT can reduce oedema in musculoskeletal injuries (Bentall, 1986; 
Markov & Pilla, 1995). Therefore, based on the upper arm circumference results from the present 
study, it appears that PEMFT can effectively reduce swelling of the upper arm.  
Regarding DOMS, which is one of the most commonly used indirect markers of eccentric 
exercise induced muscle damage (Cheung, et al., 2003), e-cell™ treatment induced a significant 
reduction in palpation soreness (Figure 26) at 2, 4 and 7 days post-exercise and about a 10% 
reduction in peak soreness (Figure 27) compared to sham treatment. There was also significantly 
faster recovery of PPT values (Figure 28) after e-cell™ treatment with significantly less tenderness 
(9 – 15%) seen everyday from 2 days post-exercise returning to baseline measures by day 4 
compared to day 7 for sham condition. This was not surprising given that Spodaryk (2002) also 
reported significantly less tenderness (∼20%) for days 3 - 5 post-exercise after applying low 
frequency PEMFT and may lend credence helps to the potential increased inhibition of group III 
and IV nerve fibres (Figure 1) which may have assisted to reduce the sensation of pain. In the 
present study, even though e-cell™ treatment attenuated palpation soreness, the magnitude of effect 
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may not be as significant as other therapeutic interventions. For example, Zainuddin et al. (2005) 
employed 10 minutes of massage therapy 3 hours after 60 maximal eccentric contractions of the 
elbow flexors that resulted in significant decreases (20 – 40%) in the severity of soreness measures 
compared to control condition. Furthermore, Lau et al. (2011) applied 30 minutes of vibration 
therapy 30 minutes and 1 - 4 days post-eccentric exercise of the elbow flexors and found significant 
reductions (25 – 30%) in peak palpation soreness between days 2 – 5. In the present study, it should 
be noted that while e-cell™ treatment attenuated palpation soreness, VAS measures from extension 
soreness were not significantly different between conditions. It is unclear why e-cell™ treatment 
would have an attenuating effect on palpation soreness and not extension soreness; but perhaps 
there are different mechanisms of pain linked to palpation soreness compared to soreness associated 
with movement that low frequency PEMFT devices may influence. Nevertheless, e-cell™ treatment 
had a small but significant attenuation of palpation and peak soreness after EIMD but is perhaps not 
as significant compared to other therapeutic interventions such as vibration therapy.  
Another indirect marker of muscle damage is plasma or serum CK activity that typically 
peaks 4 – 6 days after maximal eccentric exercise of the elbow flexors, which was confirmed in the 
present study (Clarkson, Nosaka, & Braun, 1992). Plasma CK activity increased significantly in 
both treatments after exercise; however, significantly less mean (Figure 29) and peak plasma CK 
activity (Figure 30) was seen after e-cell™ compared to sham treatment. To the best of my 
knowledge, this is the first study to show that PEMFT can attenuate increases in plasma CK 
activity. It is difficult to compare the results from the present study with other electrotherapy studies 
due to the differing treatment and exercise protocols. However, it appears the magnitude of e-cell™ 
treatment effect on plasma CK activity is greater than other electrotherapy studies. For example, 
Lau et al. (2011) and Nosaka et al. (2004) found no significant difference between their respective 
treatments (vibration and microwave diathermy respectively) and control condition on reducing 
increases in plasma CK activity. In the present study the reduced plasma CK activity after e-cell™ 
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treatment could possibly be explained by smaller CK efflux from the damaged muscle (Figure 1) 
but is unlikely to be caused by increased clearance of plasma CK from circulatory factors as no 
changes in muscle blood flow were found from Study 1. However, there is no evidence to support 
these speculations in the present study. 
 The results from the present study support the effectiveness of e-cell™ treatment in the 
attenuation of symptoms associated with EIMD. Previously, PEMFT has been shown to be effective 
in the recovery of muscle tenderness and losses in ROM following EIMD, but to the best of my 
knowledge, this is the first study to demonstrate the effectiveness of PEMFT in the recovery of 
muscle strength, soreness, swelling and plasma CK activity. Thus, the findings from this study, in 
regards to the recovery of muscle damage markers following EIMD, are important for athletes to 
assist in their recovery after training and competition as well as the general population. 
It is difficult to determine how e-cell™ treatment enhanced the recovery of muscle damage 
but some speculation is possible. It is well known that secondary muscle damage (inflammatory 
processes that follow the primary damage of eccentric exercise) associated with an inflammatory 
response can contribute to swelling and prolonged strength losses (Clarkson & Hubal, 2002). 
Additionally, inflammation in skeletal muscle is characterised by the infiltration of neutrophils and 
macrophages that are associated with muscle injury and repair (Hernandez et al., 1987). Neutrophils 
are also known to proliferate around the site of injury in the early stages of inflammation. With this 
in mind, it has been shown that adenosine (thought to be an endogenous anti-inflammatory agent 
that activates A2a receptors found on neutrophils) can bind to neutophil receptors and decrease 
inflammatory processes (Huang, Apasov, Koshiba, & Sitkovsky, 1997). Varani et al. (2002) showed 
that low frequency PEMFT exposure can significantly enhance the function and expression of 
adenosine A2a receptor activity in human neutrophils in vitro, which could play an in important role 
in modulating inflammatory processes that could benefit therapeutic healing (Cronstein, 
Montesinos, & Weissmann, 1999). Therefore, it could be speculated that e-cell™ treatment helped 
to attenuate the early inflammatory response to EIMD and facilitate the recovery of strength and 
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swelling. Electromagnetic fields are also believed to affect cell membrane function by influencing 
the rate of ion binding and transport to receptor sites and influence tissue repair (Bersani et al., 
1997; Markov, 2007). The reduced efflux of plasma CK into the blood stream reported in the 
present study may support this argument (Figure 1). As previously mentioned, PEMFT treatment 
has been shown to reduce acute/chronic inflammation occurring from musculoskeletal injuries. All 
things considered, it is believed the primary function of low frequency PEMFT treatment is to 
suppress the extravascular oedema during the early stages of an inflammatory response.  
It is not fully understood how the e-cell™ treatment attenuated palpation soreness and PPT. 
However, it could be speculated that the electromagnetic fields from low frequency PEMFT devices 
may influence DOMS and muscle tenderness by impeding the sensory input from the nociceptors to 
the afferent fibres (type Aδ and C) reducing the perception of pain (Figure 1) (Robertson et al., 
2006). As previously reported within this discussion, e-cell™ treatment also reduced swelling 
around the elbow flexors, which may have also contributed to the smaller increases in the sensitivity 
of the nociceptors to palpation soreness, as swelling is believed to contribute to hyperalgesia of the 
nociceptors (Sluka, Jordan, & Westlund, 1994). However, based upon the comparison between the 
first and second bouts of eccentric exercise for the e-cell™ treatment effect (Figure 39), it appears 
that PEMFT had the greatest attenuating effect on markers of inflammation since the greatest 
magnitude of protection conferred by e-cell™ treatment was evident on swelling (Figures 39 & 40). 
Further studies are necessary examine the underlying mechanisms of PEMFT treatment.    
 
5.2.6 Repeated Bout Effect 
In the present study, when the second bout of exercise was performed 4 weeks after the first 
bout (ignoring the treatment effect between e-cell™ and sham conditions) there were significantly 
smaller changes in all of the dependent variables on the contralateral arm compared with the first 
bout, suggesting an arm-to-arm cross transfer effect (Figure 31 - 38). At least three studies have 
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reported the existence of the contralateral repeated bout effect for the elbow flexors (Howatson & 
Van Someren, 2007; Newton, Sacco, Chapman, & Nosaka, 2013; Starbuck & Eston, 2012). 
However, it should be noted that the first and second bouts were not the same conditions such that 
one of the bouts was for e-cell™ condition and the other was for sham condition. In contrast, the 
previous studies (Howatson & Van Someren, 2007; Newton et al., 2013; Starbuck & Eston, 2012) 
investigated the contralateral repeated bout effect without any additional effect. 
For the changes in MVC torque in the present study, a significantly faster rate of recovery for 
strength was seen after bout 2 compared to bout 1, with significant differences observed on days 2 – 
5 and 7 days post-exercise with ∼12% greater strength recovery observed on day 2 after the second 
bout compared to the first, and this trend continued to day 7 (Figure 31). Previous studies have also 
reported significantly faster recovery of strength on the contralateral arm after the second bout of 
exercise compared to the first (Howatson & Van Someren, 2007; Newton et al., 2013; Starbuck & 
Eston, 2012). Our findings were similar to observations reported by Newton et al. (2013), in which 
two bouts were separated by 4 weeks, the same as that of the present study. However, the 
magnitude of strength recovery in the present study does not appear to be as significant as that 
found by Howatson and Van Someren (2007) and Starbuck and Eston (2012) whose subjects 
performed exercise bouts with only 2 weeks separation. It may be that the contralateral repeated 
bout effect is attenuated with increasing the interval between bouts as shown in the ipsilateral 
repeated bout effect (Nosaka, Sakamoto, Newton, & Sacco, 2001).  
A significantly faster rate of recovery for ROM was also observed for days 1 – 5 following 
bout 2 compared to bout 1 (Figure 32). Interestingly, previous studies exhibiting the contralateral 
repeated bout effect found no significant difference between bouts 1 and 2 for the recovery of ROM 
following EIMD (Howatson & Van Someren, 2007; Newton et al., 2013; Starbuck & Eston, 2012). 
It is not clear why significant differences in ROM were evident in the present study and not in the 
previous contralateral repeated bout studies. It must be noted that Howatson and Van Someren 
(2007) and Starbuck and Eston (2012) only measured elbow joint ROM for three time points (pre-, 
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48 and 96 hours and pre-, 24 and 48 hours respectively) instead of nine time points in the Newton et 
al. (2013) and present study which may have influenced the statistical significance of their findings.  
Besides the enhanced muscle function, there were also significantly smaller increases in upper 
arm circumference after bout 2 compared to bout 1 (Figure 33). Newton et al. (2013) also reported 
significantly less swelling after bout 2 compared to bout 1, but the magnitude of effect after the 
second bout in the present study appears to be greater given that significant differences were found 
for every time point after 60 minutes post-exercise compared to day 7 only in the Newton et al. 
(2013) study. Interestingly, Howatson and Van Someren (2007) found no significant contralateral 
repeated bout effect for upper arm circumference; although a direct comparison should not be made 
since the interval between bouts differed to the present study. Starbuck and Eston (2012) did not 
measure upper arm circumference. 
Compared to bout 1, palpation (Figure 34), peak (Figure 35) and extension soreness were all 
significantly attenuated in bout 2. Significant differences were seen from days 2 – 5 post-exercise 
for palpation soreness, while peak soreness was ∼35% lower after the second bout compared to the 
first. Similarly, the recovery of muscle tenderness was significantly faster after bout 2 compared to 
bout 1, with PPT values returning to baseline after 5 days post-exercise in the second bout 
compared to day 7 in the first bout (Figure 36). The three previous contralateral repeated bout effect 
studies did not include PPT measures. However, with regards to DOMS, Howatson and Van 
Someren (2007) and Starbuck and Eston (2012) also found significantly less muscle soreness 
develop in the elbow flexors after bout 2 compared to bout 1 although a direct comparison should 
be treated with caution as the previously mentioned studies assessed extension soreness only. In 
contrast, Newton et al. (2013) found no significant difference in extension soreness of the elbow 
flexors between the first and second bouts.  
The second bout of exercise also attenuated increases in plasma CK activity compared to the 
first with significant differences seen from day 3 onwards (Figure 37). In addition, significantly less 
(∼45%) peak plasma CK activity was evident following bout 2 compared to bout 1 (Figure 38). The 
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blunted plasma CK activity following the second bout in the present study is in accordance with 
previous studies (Howatson & Van Someren, 2007; Newton et al., 2013; Starbuck & Eston, 2012). 
These findings from the present study provide further evidence for the existence of the 
contralateral repeated bout effect. These results follow a similar trend to that found in previous 
research and suggest the adaptations to a contralateral repeated bout of exercise are primarily 
determined by centrally mediated neural mechanisms as there is no direct stimulus for cellular or 
mechanical adaptations to develop in the unexercised limb (Howatson & Van Someren, 2007; 
Newton et al., 2013; Starbuck & Eston, 2012).  It should be noted that the contralateral repeated 
effect found in the present study could be a combination of the contralateral repeated bout effect 
and the treatment effect.  
The crossover design was chosen in this study, as it requires a smaller number of subjects and 
allows for reduced variability in molecular responses to exercise created by heterogeneous subjects 
(Chen, Hubal, Hoffman, Thompson, & Clarkson, 2003). The present study showed that the 
magnitude of the e-cell™ treatment effect was greater for the first bout (the subjects who had either 
the e-cell™ or sham treatment for the first bout only were compared) than the second bout (the 
subjects who had either the e-cell™ or sham treatment for the second bout only were compared) 
using a smaller number (n=8) of subjects (Figure 40). Interestingly, the magnitude of the e-cell™ 
treatment effect was smaller for the second bout than the first bout. This suggests that the 
contralateral repeated bout effect could have affected the results such that the smaller effect found 
in the second bout was the combination of the treatment effect and the contralateral repeated bout 
effect. Importantly, the magnitude of the treatment effect found for the first bout was more similar 
to the results of the overall magnitude of treatment effect (Figure 39 & 40). Therefore, it appears 
that the crossover design is acceptable for validating the intervention. However, it should be 
cognisant that the contralateral repeated bout effect could affect the results when the arm-to-arm 
comparison model is used. Future studies assessing the effects of prophylactic or therapeutic 
interventions on muscle damage may look to extend the washout period between exercise bouts if 
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an arm-to-arm comparison model is used, or separate subjects into either control or intervention 
group so that a prior bout of exercise does not influence the outcome measures. 
 
5.2.7 Comparison between the Treatment Effect and the Repeated Bout Effect 
As discussed above, it appears that the magnitude of the contralateral repeated bout effect was 
greater than the effect of e-cell™ treatment (Figure 39). For example, on day 5 e-cell™ treatment 
only improved the rate of recovery for MVC torque, ROM, peak soreness and PPT by 
approximately 9%, 4%, 11% and 13%, respectively (Figure 40). On the other hand, the contralateral 
repeated bout effect improved the rate of recovery for the same muscle damage markers on day 5 by 
almost 18%, 8%, 35% and 20% respectively (Figure 39). It is not realistic that one arm is damaged 
to protect the other arm from muscle damage, but several studies have shown that non-damaging 
exercise consisting of either low-intensity eccentric contractions (Chen et al., 2011) or maximal 
contractions at a long muscle length (Chen, Nosaka, Pearce, & Chen, 2012) confers a protective 
effect against muscle damage induced by maximal eccentric contraction. These studies have shown 
that the magnitude of muscle damage is greatly reduced when non-damaging exercise was 
performed previously (Chen et al., 2011, Chen et al., 2012). Furthermore, it appears that the 
protective effect induced by non-damaging or pre-conditioning exercise may be greater than was 
shown by the e-cell™ treatment found in the present study. Therefore, pre-conditioning the muscle 
with a prior bout of exercise could be more effective at attenuating symptoms associated with 
EIMD compared to e-cell™ treatment.  Since there are no costs for the pre-conditioning exercise, it 
might be that e-cell™ treatment may not be the best choice for the attenuation of muscle damage 
induced by eccentric exercise.  
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5.3 Conclusion 
In summary, the present study showed recovery of muscle damage markers were faster with 
e-cell™ treatment compared with sham treatment. However, it is evident that the contralateral 
repeated bout effect may have been a confounding factor that provided a protective effect in the 
second bout of exercise for both conditions. It has been reported that pre-conditioning the muscle 
using maximal isometric contractions or sub-maximal eccentric exercise, which are non-damaging, 
can have a strong protective effect against muscle damage. However, it is not known whether the 
magnitude of the protective effect conferred by pre-conditioning exercise is stronger than the 
magnitude of the e-cell™ treatment effect. Therefore, if the e-cell™ treatment effect is weaker than 
the effect of pre-conditioning exercise, then pre-conditioning exercise should be recommended in 
preference to e-cell™ treatment because it can be administered with minimal cost and the equipment 
can be easier to access. However, if no pre-conditioning exercise was performed, and muscle 
damage was induced, e-cell™ treatment seems to be a good option to enhance recovery from 
eccentric exercise-induced muscle damage. There are many causes of muscle damage, and eccentric 
exercise-induced muscle damage is only one of them. Further studies are necessary to investigate 
the effect of e-cell™ treatment on other soft tissue injuries, since it is anecdotally believed to 
enhance recovery from more severe injuries such as a skeletal muscle tears. 
 
 76 
REFERENCES 
 
Aaron, R., Lennox, D., Bunce, G., & Ebert, T. (1989). The conservative treatment of osteonecrosis 
of the femoral head: A comparison of core decompression and pulsing electromagnetic 
fields. Clinical Orthopaedics and related Research, 249(3), 209-218.  
Adey, W. R. (1993). Biological effects of electromagnetic fields. Journal of Cellular Biochemistry, 
51(2), 410-410.  
Allen, J. D., Mattacola, C. G., & Perrin, D. H. (1999). Effect of microcurrent stimulation on 
delayed-onset muscle soreness: a double-blind comparison. Journal of Athletic Training, 
34(4), 334-337.  
Ayles, S., Graven-Nielsen, T., & Gibson, W. (2011). Vibration-induced afferent activity augments 
delayed onset muscle allodynia. The Journal of Pain, 12(8), 884-891.  
Aytar, A., Tuzun, E. H., Eker, L., Yuruk, Z. O. B., Daskapan, A., & Akman, M. N. (2008). 
Effectiveness of low-dose pulsed ultrasound for treatment of delayed-onset muscle soreness: 
A double-blind randomized controlled trial. Isokinetics and Exercise Science, 16(4), 239-
247.  
Bakhtiary, A. H., Safavi-Farokhi, Z., & Aminian-Far, A. (2007). Influence of vibration on delayed 
onset of muscle soreness following eccentric exercise. British Journal of Sports Medicine, 
41(3), 145-148.  
Baldwin, A. C., Stevenson, S. W., & Dudley, G. A. (2001). Nonsteroidal Anti-Inflammatory 
Therapy After Eccentric Exercise in Healthy Older Individuals. The Journals of 
Gerontology Series A: Biological Sciences and Medical Sciences, 56(8), 510-513.  
Balnave, C. D., & Thompson, M. W. (1993). Effect of training on eccentric exercise-induced 
muscle damage. Journal of Applied Physiology, 75(4), 1545-1551.  
Baroni, B. M., Junior, E. C. P. L., De Marchi, T., Lopes, A. L., Salvador, M., & Vaz, M. A. l. 
(2010). Low level laser therapy before eccentric exercise reduces muscle damage markers in 
humans. European Journal of Applied Physiology, 110(4), 789-796.  
Bentall, R. (1986). Low-level pulsed radiofrequency fields and the treatment of soft-tissue injuries. 
Bioelectrochemistry and Bioenergetics, 16(3), 531-548.  
Bersani, F., Marinelli, F., Ognibene, A., Matteucci, A., Cecchi, S., Santi, S., et al. (1997). 
Intramembrane protein distribution in cell cultures is affected by 50 Hz pulsed magnetic 
fields. Bioelectromagnetics, 18(7), 463-469.  
Bertolucci, L. E., & Grey, T. (1995). Clinical comparative study of microcurrent electrical 
stimulation to mid-laser and placebo treatment in degenerative joint disease of the 
temporomandibular joint. Cranio: the Journal of Craniomandibular Practice, 13(2), 116.  
Bonacci, J. A., & Higbie, E. J. (1997). Effects of microcurent treatment on perceived pain and 
muscle strength following eccentric exercise Journal of Athletic Training, 32(2), 119-123.  
Bougie, J. (1997). Management for delayed-onset muscular soreness: A review of the literature. 
Journal of Sports Chiropractic & Rehabilitation, 11(1), 1-10.  
Brighton, C. T., & Friedenberg, Z. (1974). Electrical Stimulation and Oxygen Tension. Annals of 
the New York Academy of Sciences, 238(1), 314-320.  
Broadbent, S., Rousseau, J. J., Thorp, R. M., Choate, S. L., Jackson, F. S., & Rowlands, D. S. 
(2010). Vibration therapy reduces plasma IL6 and muscle soreness after downhill running. 
British Journal of Sports Medicine, 44(12), 888-894.  
Brukner, P., & Khan, K. (2002). Clinical Sports Medicine (2nd ed.). Sydney: McGraw-Hill. 
 77 
Bryer, S. C., & Goldfarb, A. H. (2006). Effect of high dose vitamin C supplementation on muscle 
soreness, damage, function, and oxidative stress to eccentric exercise. International Journal 
of Sport Nutrition and Exercise Metabolism, 16(3), 270-280.  
Burgess, T. L., & Lambert, M. I. (2010). The efficacy of cryotherapy on recovery following 
exercise-induced muscle damage. International SportMed Journal, 11(2), 258-277.  
Byrnes, W. C., Clarkson, P. M., White, J. S., Hsieh, S. S., Frykman, P. N., & Maughan, R. J. 
(1985). Delayed onset muscle soreness following repeated bouts of downhill running. 
Journal of Applied Physiology, 59(3), 710-715.  
Callam, M. J., Harper, D. R., Dale, J. J., Ruckley, C. V., & Prescott, R. J. (1987). A controlled trial 
of weekly ultrasound therapy in chronic leg ulceration. Lancet, 2(8552), 204-206.  
Carter, A., Dobridge, J., & Hackney, A.C. (2001). Influence of estrogen on markers of muscle 
tissue damage following eccentric exercise. Human Physiology, 27(5), 133-137. 
Chapman, D., Newton, M., Sacco, P., & Nosaka, K. (2006). Greater muscle damage induced by fast 
versus slow velocity eccentric exercise. International Journal of Sports Medicine, 27(8), 
591-598.  
Chapman, D. W., Newton, M., Mcguigan, M., & Nosaka, K. (2008). Effect of lengthening 
contraction velocity on muscle damage of the elbow flexors. Medicine and Science in Sports 
and Exercise, 40(5), 926-933.  
Chen, C. H., Nosaka, K., Chen, H. L., Lin, M. J., Tseng, K. W., & Chen, T. C. (2011). Effects of 
flexibility training on eccentric exercise-induced muscle damage. Medicine & Science in 
Sports & Exercise, 43(3), 491-500.  
Chen, H. L., Nosaka, K., Pearce, A. J., & Chen, T. C. (2012). Two maximal isometric contractions 
attenuate the magnitude of eccentric exercise-induced muscle damage. Applied Physiology, 
Nutrition and Metabolism, 37(4), 680-689.  
Chen, T. C., Chen, H. L., Pearce, A. J., & Nosaka, K. (2012). Attenuation of eccentric exercise-
induced muscle damage by preconditioning exercises. Medicine & Science in Sports & 
Exercise, 44(11), 2090-2098.  
Chen, T. C., Lin, K. Y., Chen, H. L., Lin, M. J., & Nosaka, K. (2011). Comparison in eccentric 
exercise-induced muscle damage among four limb muscles. European Journal of Applied 
Physiology, 111(2), 211-223.  
Chen, T. C., Nosaka, K., & Sacco, P. (2007). Intensity of eccentric exercise, shift of optimum angle, 
and the magnitude of repeated-bout effect. Journal of Applied Physiology, 102(3), 992-999.  
Chen, Y.-W., Hubal, M. J., Hoffman, E. P., Thompson, P. D., & Clarkson, P. M. (2003). Molecular 
responses of human muscle to eccentric exercise. Journal of Applied Physiology, 95(6), 
2485-2494.  
Cheng, N., Van Hoof, H., Bockx, E., Hoogmartens, M. J., Mulier, J. C., De Dijker, F. J., et al. 
(1982). The effects of electric currents on ATP generation, protein synthesis, and membrane 
transport in rat skin. Clinical orthopaedics and related research, 171, 264-272.  
Chesterton, L. S., Barlas, P., Foster, N. E., Baxter, G. D., & Wright, C. C. (2003). Gender 
differences in pressure pain threshold in healthy humans. Pain, 101(3), 259-266.  
Cheung, K., Hume, P., & Maxwell, L. (2003). Delayed onset muscle soreness : treatment strategies 
and performance factors. Sports Medicine, 33(2), 145-164.  
Chow, R. T., Heller, G. Z., & Barnsley, L. (2006). The effect of 300mW, 830nm laser on chronic 
neck pain: A double-blind, randomized, placebo-controlled study. Pain, 124(1), 201-210.  
Clarkson, P. M., & Hubal, M. J. (2002). Exercise-induced muscle damage in humans. American 
Journal of Physical Medicine & Rehabilitation, 81(11), 52-69.  
Clarkson, P. M., Nosaka, K., & Braun, B. (1992). Muscle function after exercise-induced muscle 
damage and rapid adaptation. Medicine & Science in Sports & Exercise, 24(5), 512-520.  
Clarkson, P. M., & Tremblay, I. (1988). Exercise-Induced Muscle Damage, Repair, and Adaptation 
in Humans. Journal of Applied Physiology, 65(1), 1-6.  
 78 
Cleak, M. J., & Eston, R. G. (1992). Muscle soreness, swelling, stiffness and strength loss after 
intense eccentric exercise. British Journal of Sports Medicine, 26(4), 267-272.  
Collis, C., & Segal, M. (1988). Effects of pulsed electromagnetic fields on Na+ fluxes across 
stripped rabbit colon epithelium. Journal of Applied Physiology, 65(1), 124-130.  
Connolly, D. A., Sayers, S. P., & McHugh, M. P. (2003). Treatment and prevention of delayed 
onset muscle soreness. Journal of Strength & Conditioning Research, 17(1), 197-208.  
Craig, J. A., Barron, J., Walsh, D. M., & Baxter, G. D. (1999). Lack of effect of combined low 
intensity laser therapy/phototherapy(CLILT) on delayed onset muscle soreness in humans. 
Lasers in surgery and medicine, 24(3), 223-230.  
Craig, J. A., Bradley, J., Walsh, D. M., Baxter, G. D., & Allen, J. M. (1999). Delayed onset muscle 
soreness: lack of effect of therapeutic ultrasound in humans. Archives of Physical Medicine 
and Rehabilitation, 80(3), 318-323.  
Craig, J. A., Cunningham, M. B., Walsh, D. M., Baxter, G. D., & Allen, J. M. (1996). Lack of 
effect of transcutaneous electrical nerve stimulation upon experimentally induced delayed 
onset muscle soreness in humans. Pain, 67(2), 285-289.  
Cronstein, B., Montesinos, M., & Weissmann, G. (1999). Sites of action for future therapy: an 
adenosine-dependent mechanism by which aspirin retains its antiinflammatory activity in 
cyclooxygenase-2 and NFkappaB knockout mice. Osteoarthritis and Cartilage, 7(4), 361-
363.  
Curtis, D., Fallows, S., Morris, M., & McMakin, C. (2010). The efficacy of frequency specific 
microcurrent therapy on delayed onset muscle soreness. Journal of Bodywork and 
Movement Therapies, 14(3), 272-279.  
Deighan, M., De Ste Croix, M., Grant, C., & Armstrong, N. (2006). Measurement of maximal 
muscle cross-sectional area of the elbow extensors and flexors in children, teenagers and 
adults. Journal of Sports Science, 24(5), 543-546.  
Denegar, C. R., & Perrin, D. H. (1992). Effect of transcutaneous electrical nerve stimulation, cold, 
and a combination treatment on pain, decreased range of motion, and strength loss 
associated with delayed onset muscle soreness. Journal of Athletic Training, 27(3), 200-206.  
Dyson, M. (1987). Mechanisms involved in therapeutic ultrasound. Physiotherapy, 73(3), 116-120.  
Ebenbichler, G. R., Resch, K. L., Nicolakis, P., Wiesinger, G. n. F., Uhl, F., Ghanem, A.-H., et al. 
(1998). Ultrasound treatment for treating the carpal tunnel syndrome: randomised controlled 
trial. British Medical Journal, 316(7133), 731.  
Enwemeka, C. S. (2001). Attenuation and penetration of visible 632.8 nm and invisible infra-red 
904nm light in soft tissues. Laser, 13(2), 96.  
Fleckenstein, J. L., & Shellock, P. D. (1992). Exertional muscle injuries: magnetic resonance 
imaging evaluation. Techniques in Orthopaedics, 7(3), 1-22.  
Gandevia, S. (2001). Spinal and supraspinal factors in human muscle fatigue. Physiological 
reviews, 81(4), 1725-1789.  
Giombini, A., Di Cesare, A., Safran, M. R., Ciatti, R., & Maffulli, N. (2006). Short-term 
Effectiveness of Hyperthermia for Supraspinatus Tendinopathy in Athletes A Short-term 
Randomized Controlled Study. The American journal of sports medicine, 34(8), 1247-1253.  
Gleeson, M., Blannin, A. K., Walsh, N. P., Field, C. N., & Pritchard, J. C. (1998). Effect of 
exercise-induced muscle damage on the blood lactate response to incremental exercise in 
humans. European Journal of Applied Physiology and Occupational Physiology, 77(3), 292-
295.  
Gur, A., Karakoc, M., Nas, K., Cevik, R., Sarac, J., & Demir, E. (2002). Efficacy of low power 
laser therapy in fibromyalgia: a single-blind, placebo-controlled trial. Lasers in medical 
science, 17(1), 57-61.  
Hasson, S., Mundorf, R., Barnes, W., Williams, J., & Fujii, M. (1990). Effect of pulsed ultrasound 
versus placebo on muscle soreness perception and muscular performance. Scandinavian 
Journal of Rehabilitation Medicine, 22(4), 199.  
 79 
Hasson, S. M., Daniels, J. C., Divine, J. G., Niebuhr, B. R., Richmond, S., Stein, P. G., et al. (1993). 
Effect of ibuprofen use on muscle soreness, damage, and performance: a preliminary 
investigation. Medicine & Science in Sports & Exercise, 25(1), 9-17.  
Hedan, P., & Pilla, A. (2008). Effect of pulsed electromagnetic fields on postoperative pain: a 
double blind randomized pilot study in breast augmentation patients. Aesthetic Plastic 
Surgery, 32(4), 660-666.  
Hernandez, L., Grisham, M., Twohig, B., Arfors, K., Harlan, J., & Granger, D. (1987). Role of 
neutrophils in ischemia-reperfusion-induced microvascular injury. American Journal of 
Physiology-Heart and Circulatory Physiology, 253(3), 699-703.  
Howatson, G., & Van Someren, K. (2007). Evidence of a contralateral repeated bout effect after 
maximal eccentric contractions. European Journal of Applied Physiology, 101(2), 207-214.  
Howatson, G., & Van Someren, K. A. (2003). Ice massage. Effects on exercise-induced muscle 
damage. The Journal of Sports Medicine & Physical Fitness, 43(4), 500-505.  
Howatson, G., & van Someren, K. A. (2008). The prevention and treatment of exercise-induced 
muscle damage. Sports Medicine, 38(6), 483-503.  
Huang, S., Apasov, S., Koshiba, M., & Sitkovsky, M. (1997). Role of A2a extracellular adenosine 
receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and 
expansion. Blood, 90(4), 1600-1610.  
Jakeman, J. R., Byrne, C., & Eston, R. G. (2010). Lower limb compression garment improves 
recovery from exercise-induced muscle damage in young, active females. European Journal 
of Applied Physiology, 109(6), 1137-1144.  
Johansson, P. H., Lindstrom, L., Sundelin, G., & Lindstrom, B. (1999). The effects of preexercise 
stretching on muscular soreness, tenderness and force loss following heavy eccentric 
exercise. Scandinavian Journal of Medicine & Science in Sports, 9(4), 219-225.  
Johnson, M., Ashton, C., & Thompson, J. (1991). An in-depth study of long-term users of 
transcutaneous electrical nerve stimulation (TENS). Implications for clinical use of TENS. 
Pain, 44(3), 221-229.  
Jones, D. A., Newham, D. J., & Clarkson, P. M. (1987). Skeletal muscle stiffness and pain 
following eccentric exercise of the elbow flexors. Pain, 30(2), 233-242.  
Junior, E. C. P. L., Lopes-Martins, R. B., Vanin, A. A., Baroni, B. M., Grosselli, D., De Marchi, T., 
et al. (2009). Effect of 830 nm low-level laser therapy in exercise-induced skeletal muscle 
fatigue in humans. Lasers in medical science, 24(3), 425-431.  
Kavaliers, M., Choleris, E., Prato, F., & Ossenkopp, K. (1998). Evidence for the involvement of 
nitric oxide synthase in the modulation of opioid-induced antinociception and the inhibitory 
effects of exposure to 60-Hz magnetic fields in the land snail. Brain Research, 809(7), 50-
57. 
Kellis, E., & Baltzopoulos, V. (1998). Muscle activation differences between eccentric and 
concentric isokinetic exercise. Medicine and Science in Sports and Exercise, 30(11), 1616-
1623.  
Kendall, B., & Eston, R. (2002). Exercise-induced muscle damage and the potential protective role 
of estrogen. Sports Medicine, 32(2), 103-123.  
Kraemer, W. J., Bush, J. A., Wickham, R., Denegar, C., Gomez, A., Gotshalk, L., et al. (2001). 
Influence of compression therapy on symptoms following soft tissue injury from maximal 
eccentric exercise. The Journal of orthopaedic and sports physical therapy, 31(6), 282-297.  
Landis, J. R., & Koch, G. G. (1977). The measurement of observer agreement for categorical data. 
Biometrics, 33(1), 159-174.  
Lau, W. Y., & Nosaka, K. (2011). Effect of Vibration Treatment on Symptoms Associated with 
Eccentric Exercise-Induced Muscle Damage. American Journal of Physical Medicine & 
Rehabilitation, 90(8), 648-657.  
 80 
Leal Junior, E. C. P., Lopes-Martins, R. B., Dalan, F., Ferrari, M., Sbabo, F. M., Generosi, R. A., et 
al. (2008). Effect of 655-nm low-level laser therapy on exercise-induced skeletal muscle 
fatigue in humans. Photomedicine and laser surgery, 26(5), 419-424.  
Lee, E. W. C., Maffulli, N., Li, C. K., & Chan, K. M. (1997). Pulsed magnetic and electromagnetic 
fields in experimental achilles tendonitis in the rat: a prospective randomized study. 
Archives of Physical Medicine and Rehabilitation, 78(4), 399-404.  
Lundeberg, T., Nordemar, R., & Ottoson, D. (1984). Pain alleviation by vibratory stimulation. Pain, 
20(1), 25-44.  
Mancinelli, C. A., Davis, D. S., Aboulhosn, L., Brady, M., Eisenhofer, J., & Foutty, S. (2006). The 
effects of massage on delayed onset muscle soreness and physical performance in female 
collegiate athletes. Physical Therapy in Sport, 7(1), 5-13.  
Markov, M., & Pilla, A. (1995). Electromagnetic-field stimulation of soft-tissues-pulsed radio-
frequency treatment of postoperative pain and edema. Wounds: a Compendium of Clinical 
Research and Practice, 7(4), 143-151.  
Markov, M. S. (2007). Expanding use of pulse electromagnetic field therapies. Electromagnetic 
Biology and Medicine, 26(4), 257-274.  
Maxwell, S. R., Jakeman, P., Thomason, H., Leguen, C., & Thorpe, G. H. (1993). Changes in 
plasma antioxidant status during eccentric exercise and the effect of vitamin 
supplementation. Free Radical Research Communications, 19(3), 191-202.  
Melzack, R., & Wall, P. D. (1967). Pain mechanisms: a new theory. Survey of Anesthesiology, 
11(2), 89-90.  
Mollon, B., da Silva, V., Busse, J. W., Einhorn, T. A., & Bhandari, M. (2008). Electrical 
stimulation for long-bone fracture-healing: a meta-analysis of randomized controlled trials. 
The Journal of Bone & Joint Surgery, 90(11), 2322-2330.  
Mooney, V. (1990). A randomized double-blind prospective study of the efficacy of pulsed 
electromagnetic fields for interbody lumbar fusions. Spine, 15(7), 708-712.  
Newton, M., Morgan, G. T., Sacco, P., Chapman, D. W., & Nosaka, K. (2008). Comparison of 
responses to strenuous eccentric exercise of the elbow flexors between resistance trained 
and untrained men. Journal of Strength & Conditioning, 22(2), 597-607.  
Newton, M. J., Sacco, P., Chapman, D., & Nosaka, K. (2013). Do dominant and non-dominant arms 
respond similarly to maximal eccentric exercise of the elbow flexors? Journal of Science 
and Medicine in Sport, 16(2), 166-171.  
Nosaka, K. (2008). Muscle soreness, muscle damage and repeated bout effect. In P. M. Tiidus 
(Ed.), Skeletal Muscle Damage and Repair (pp. 59-76). Champaign, IL: Human Kinetics. 
Nosaka, K., & Clarkson, P. M. (1995). Muscle Damage Following Repeated Bouts of High Force 
Eccentric Exercise. Medicine and Science in Sports and Exercise, 27(9), 1263-1269.  
Nosaka, K., & Clarkson, P. M. (1996). Changes in indicators of inflammation after eccentric 
exercise of the elbow flexors. Medicine and Science in Sports and Exercise, 28(8), 953-961.  
Nosaka, K., & Clarkson, P. M. (1997). Influence of previous concentric exercise on eccentric 
exercise-induced muscle damage. Journal of Sports Sciences, 15(5), 477-483.  
Nosaka, K., Muthalib, M., Lavender, A., & Laursen, P. (2007). Attenuation of muscle damage by 
preconditioning with muscle hyperthermia 1-day prior to eccentric exercise. European 
Journal of Applied Physiology, 99(2), 183-192.  
Nosaka, K., & Newton, M. (2002). Difference in the magnitude of muscle damage between 
maximal and submaximal eccentric loading. Journal of Strength & Conditioning Research, 
16(2), 202-208.  
Nosaka, K., Newton, M., & Sacco, P. (2002). Muscle damage and soreness after endurance exercise 
of the elbow flexors. Medicine & Science in Sports & Exercise, 34(6), 920-927.  
Nosaka, K., Newton, M., Sacco, P., Chapman, D., & Lavender, A. (2005). Partial protection against 
muscle damage by eccentric actions at short muscle lengths. Medicine & Science in Sports 
Exercise, 37(5), 746-753.  
 81 
Nosaka, K., Newton, M. J., & Sacco, P. (2005). Attenuation of protective effect against eccentric 
exercise-induced muscle damage. Canadian Journal of Applied Physiology, 30(5), 529-542.  
Nosaka, K., & Sakamoto, K. (2001). Effect of elbow joint angle on the magnitude of muscle 
damage to the elbow flexors. Medicine & Science in Sports & Exercise, 33(1), 22-29.  
Nosaka, K., Sakamoto, K., Newton, M., & Sacco, P. (2001). How long does the protective effect on 
eccentric exercise-induced muscle damage last? Medicine in Science & Sports Exercise, 
33(9), 1490-1495.  
Nosaka, K., Sakamoto, K., Newton, M., & Sacco, P. (2004). Influence of pre-exercise muscle 
temperature on responses to eccentric exercise. Journal of Athletic Training, 39(4), 132-137.  
Pizza, F. X., Koh, T. J., McGregor, S. J., & Brooks, S. V. (2002). Muscle inflammatory cells after 
passive stretches, isometric contractions, and lengthening contractions. Journal of Applied 
Physiology, 92(5), 1873-1878.  
Pournot, H., Bieuzen, F., Duffield, R., Lepretre, PM., Cozzolino, C., & Hausswirth, C. (2011). 
Short term effects of various water immersions on recovery from exhaustive intermittent 
exercise. European Journal of Applied Physiology, 111(7), 1287-1295. 
Rinard, J., Clarkson, P. M., Smith, L. L., & Grossman, M. (2000). Response of males and females 
to high-force eccentric exercise. Journal of Sports Science, 18(4), 229-236.  
Robertson, V., Ward, A., Low, J., & Reed, A. (2006). Electrotherapy Explained: Principles and 
Practices (4th ed.). London: Elsevier Ltd. 
Saka, T., Akova, B., Yazici, Z., Sekir, U., Gur, H., & Ozarda, Y. (2009). Differences in the 
magnitude of muscle damage between elbow flexors and knee extensors eccentric exercise. 
Journal of Sports Science and Medicine, 8(3), 107-115.  
Sayers, S. P., & Clarkson, P. M. (2001). Force recovery after eccentric exercise in males and 
females. European Journal of Applied Physiology, 84(1-2), 122-126.  
Seawright, K. A., Hubal, M. J., Kearns, A., Holbrook, M. T., & Clarkson, P. M. (2008). Sex 
differences in response to maximal eccentric exercise. Medicine & Science in Sports & 
Exercise, 40(2), 242-251.  
Sharrard, W. (1990). A double-blind trial of pulsed electromagnetic fields for delayed union of 
tibial fractures. Journal of Bone & Joint Surgery, 72(3), 347-355.  
Sluka, K., Jordan, H., & Westlund, K. N. (1994). Reduction in joint swelling and hyperalgesia 
following post-treatment with a non-NMDA glutamate receptor antagonist. Pain, 59(1), 95-
100.  
Sluka, K. A., Deacon, M., Stibal, A., Strissel, S., & Terpstra, A. (1999). Spinal blockade of opioid 
receptors prevents the analgesia produced by TENS in arthritic rats. Journal of 
Pharmacology and Experimental Therapeutics, 289(2), 840-846.  
Spodaryk, K. (2002). The effect of extremely weak electromagnetic field treatments upon signs and 
symptoms of delayed onset of muscle soreness: A placebo controlled clinical double blind 
study. Medicina Sportiva, 12(6), 19-25.  
Starbuck, C., & Eston, R. G. (2012). Exercise-induced muscle damage and the repeated bout effect: 
evidence for cross transfer. European Journal of Applied Physiology, 112(3), 1005-1013.  
Stay, J. C., Richard, M. D., Draper, D. O., Schulthies, S. S., & Durrant, E. (1998). Pulsed 
ultrasound fails to diminish delayed-onset muscle soreness symptoms. Journal of Athletic 
Training, 33(4), 341.  
Stupka, N., Lowther, S., Chorneyko, K., Bourgeois, J., Hogben, C., & Tarnopolsky, M. (2000). 
Gender differences in muscle inflammation after eccentric exercise. Journal of Applied 
Physiology, 89(6), 2325-2332.  
Szymanski, D. J. (2001). Recommendations for the avoidance of delayed-onset muscle soreness. 
Strength & Conditioning Journal, 23(4), 7-12.  
Tepper, O. M., Callaghan, M. J., Chang, E. I., Galiano, R. D., Bhatt, K. A., Baharestani, S., et al. 
(2004). Electromagnetic fields increase in vitro and in vivo angiogenesis through endothelial 
 82 
release of FGF-2. The Federation of American Societies for Experimental Biology Journal, 
18(11), 1231-1247.  
Tiidus, P., Cort, J., Woodruff, S., & Bryden, P. (2002). Ultrasound treatment and recovery from 
eccentric-exercise-induced muscle damage. Journal of Sport Rehabilitation, 11(4), 305-314.  
Tourville, T. W., Connolly, D. A. J., & Reed, B. V. (2006). Effects of sensory-level high-volt 
pulsed electrical current ondelayed-onset muscle soreness. Journal of Sports Sciences, 
24(9), 941-949.  
Trock, D. H., Bollet, A. J., Dyer Jr, R. H., Fielding, P. L., Miner, K. W., & Markoll, R. (1993). A 
double-blinded trial of the clinical effects of pulsed electromagnetic fields in osteoarthritis. 
The Journal of Rheumatology, 20(3), 456-460.  
Vaile, J. M., Gill, N. D., & Blazevich, A. J. (2007). The effect of contrast water therapy on 
symptoms of delayed onset muscle soreness. The Journal of Strength & Conditioning 
Research, 21(3), 697-702.  
Varani, K., Gessi, S., Merighi, S., Iannotta, V., Cattabriga, E., Spisani, S., et al. (2002). Effect of 
low frequency electromagnetic fields on A2A adenosine receptors in human neutrophils. 
British journal of pharmacology, 136(1), 57-66.  
Warren, G. L., Lowe, D. A., & Armstrong, R. B. (1999). Measurement tools used in the study of 
eccentric contraction-induced injury. Sports Medicine, 27(1), 43-59.  
Watson, T. (2008). Electrotherapy: evidence-based practice. Elsevier Health Sciences. 
Weber, M. D., Servedio, F. J., & Woodall, W. R. (1994). The effects of three modalities on delayed 
onset muscle soreness. Journal of Orthopaedic & Sports Physical Therapy, 20(5), 236-242.  
Weintraub, M. I., & Cole, S. P. (2008). A randomized controlled trial of the effects of a 
combination of static and dynamic magnetic fields on carpal tunnel syndrome. Pain 
Medicine, 9(5), 493-504.  
Yanagisawa, O., Miyanaga, Y., Shiraki, H., Shimojo, H., Mukai, N., Niitsu, M., et al. (2003). The 
effects of various therapeutic measures on shoulder range of motion and cross-sectional 
areas of rotator cuff muscles after baseball pitching. Journal of Sports Medicine and 
Physical Fitness, 43(3), 356-366.  
Yarnitskya, D., Kunin, M., Brik, R., & Sprecher, E. (1997). Vibration reduces thermal pain in 
adjacent dermatones. Pain, 69(1), 75-77.  
Young, S., & Dyson, M. (1990). Effect of therapeutic ultrasound on the healing of full-thickness 
excised skin lesions. Ultrasonics, 28(3), 175-180.  
Zainuddin, A., Newton, M., Sacco, P., & Nosaka, K. (2005). Effect of massage on delayed onset 
muscle soreness, swelling and recovery of muscle function. Journal of Athletic Training, 
40(3), 174-180.  
Zainuddin, A., Sacco, P., Newton, M., & Nosaka, K. (2006). Light concentric exercise has a 
temporarily analgesic effect on delayed onset msucle soreness, but no effect on recovery 
from eccentric exercise. Applied Physiology, Nutrition, and Metabolism, 31(2), 126-134.  
Zampetaki, A., Kirton, J. P., & Xu, Q. (2008). Vascular repair by endothelial progenitor cells. 
Cardiovascular Research, 78(3), 413-421. 
 
 
 
 
 
 83 
APPENDICES 
 
APPENDIX A: ETHICS APPROVAL 
 
 84 
APPENDIX B: STUDY 1 - INFORMATION LETTER 
Information Letter to Participants   
 
Title of the Project: Effects of Pulsed Electromagnetic Field Therapy on Symptoms 
Associated with Eccentric Exercise-Induced Muscle Damage. 
Study 1 
Investigator: Harry Banyard (MSc. Candidate) 
Principle Supervisor: Professor Ken Nosaka 
Co-Supervisor: Associate Professor Michael Newton 
 
School of Exercise, Biomedical and Health Sciences 
Edith Cowan University 
270 Joondalup Drive, Joondalup WA 6027 
 
Thank you for expressing an interest in the study. The purpose of this information letter is to 
provide you with an overview of the study in which you may participate in as a subject. 
 
Purpose of the study 
The purpose of this study is to investigate whether 30 minutes of e-cell™ treatment increases 
muscle temperature, blood flow and oxygenation when it is applied to the elbow flexor muscles (in 
particular the biceps brachii). 
 
Background 
Pulsed electromagnetic field therapy (PEMFT) is a therapeutic treatment that produces magnetic 
waves to penetrate deeply through tissues without contact, where the magnetic pulses are believed 
to enhance cellular repair. Previous research has shown PEMFT to reduce pain, swelling and 
inflammation relating to musculoskeletal injuries, and enhance the tissue regeneration process. For 
this to occur it seems likely that PEMFT can increase muscle oxygenation and blood flow, but no 
previous study has investigated the effects of PEMFT on muscle temperature or these other factors. 
A portable PEMFT device called e-cell™ produces low frequency, low power electromagnetic 
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fields, and has been anecdotally claimed to enhance the healing processes of soft tissue injuries. 
Therefore this will be the first study to investigate whether PEMFT can enhance muscle 
temperature, muscle oxygenation and blood flow simultaneously. 
 
Methods 
As a participant in this study you are required to attend 2 testing sessions (24 hours apart) for a 
duration of approximately 45 mins/session at Edith Cowan University, Joondalup Campus, 
commencing in the exercise physiology lab, building 19, room 19.150. A company (Global Energy 
Medicine) has provided two e-cell devices that generate electromagnetic pulses at different 
frequencies. You and the investigator are blinded to the devices (only informed as Device A and 
Device B). The testing session will involve a series of assessments designed to test the effectiveness 
of the e-cell™ device to increase muscle temperature, muscle oxygenation and blood flow. 
 
Subjects 
As a volunteer, you must be aged between 18 to 45 years for this study. You must complete an 
informed written consent form and a medical questionnaire before participating in the study.  
 
Procedure 
During the testing session one arm will receive e-cell™ treatment at a low frequency and for the 
other testing session the other arm will receive treatment at a different frequency. You will be asked 
to lay supine on a massage table and required to keep your treatment arm as still as possible until 
the treatment period concludes to minimise changes in blood flow due to movements. The device 
(similar in shape and size to a computer mouse and weighing approximately 100g) will be placed 
longitudinally along the lateral aspect of your biceps brachii (outer upper arm) and held in place by 
a Velcro strap. The treatment will be applied for 30 min. The device will be switched on, where 
green and red lights will flash to indicate it is operating and then turned off after 30 min of 
treatment indicated by the sound of a double beep. 
 
Muscle Temperature 
A thermometer will measure your biceps brachii muscle temperature with a needle thermistor probe 
that will be inserted to a depth of 20 mm at a 45 angle into the belly of your biceps brachii. Three 
measurements will be taken 5 min before, immediately after, and 10 min after treatment. 
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Muscle Oxygenation and Blood flow 
Near infrared spectroscopy (NIRS) is a non-invasive technique that will be employed to monitor 
muscle oxygenation and blood flow in the biceps brachii muscles. The probe unit of the NIRS 
system will be firmly attached to the skin at the mid-belly of your biceps brachii with double-sided 
adhesive tape to ensure no sliding of the probe on the skin. The NIRS probe in relation to the 
treatment device will be aligned adjacently. The NIRS system will record your muscle oxygenation 
and blood flow levels commencing 5 min prior (resting value) to “e-cell” treatment and continue 
until 10 min after the “e-cell” treatment concludes. 
 
Potential Risks 
In very rare instances, the muscle temperature procedure can lead to bleeding or bruising that might 
cause pain and make using the muscle difficult for a few days. To avoid the chances of infection, 
the investigator will wear gloves and use a sterilized needle. The insertion site will also be cleaned 
and prepared with alcohol wipes.  
 
Potential Benefits 
You will have the chance to observe how current research techniques are performed and you may 
also gain an insight and understanding about the test involved. 
 
Privacy and Confidentiality 
All information collected during this research remains confidential and will not be used for any 
other purpose other than this study. All data collected will be stored securely on ECU premises and 
kept for 5 years after the completion of the project and then destroyed. 
 
Participation in the Study 
Participation in this research is entirely voluntary and you may refuse to participate or withdraw at 
anytime without adverse consequences. 
If you have any questions about the research project or require further information you may contact 
the following:  
 
Student Researcher: Henry Banyard  
Telephone: (08) 6 304 5156  
Email: h.banyard@ecu.edu.au  
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Principal Supervisor: Prof. Ken Nosaka  
Telephone: (08) 6 304 5655 
Email: k.nosaka@ecu.edu.au 
 
Co-Supervisor: Associate Prof. Michael Newton  
Telephone: (08) 6 304 4132 
Email: m.newton@ecu.edu.au 
 
If you have any ethical concerns with regards to your participation in this study you may contact:  
 
Research Ethics Officer: Kim Gifkins   
Phone: (08) 9304 2170  
Address: Human Research Ethics Committee, Edith Cowan University, 100 Joondalup Drive, 
Joondalup WA, 6027 
Email: research.ethics@ecu.edu.au  
 
Thank you for your time,  
 
Yours sincerely,  
 
Harry Banyard 
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APPENDIX C: STUDY 1 - INFORMED CONSENT FORM 
Subject Informed Consent Form                  
Study 1 
 
I ___________________________, consent to participating in the research project entitled: 
“Effects of Pulsed Electromagnetic Field Therapy on Symptoms Associated with 
Eccentric Exercise-Induced Muscle Damage”.  
 
Statement indicating consent to participate 
I confirm the following: 
• I have been provided with the “Information Letter” explaining the research study 
• I have read and understood the information provided and the procedures of the study 
• I have been given an opportunity to ask questions and I have had any questions answered to 
my satisfaction 
• I am aware that if I have any additional questions, I can contact the research team 
• I understand that participation in the research project will involve: 
o Two testing sessions where one arm will receive e-cell™ treatment and the other arm 
will receive sham treatment 
o Measurements of muscle temperature, muscle oxygenation and muscle blood flow 
o Possible muscle soreness after muscle temperature measurements 
• I understand that my information provided will be kept confidential, and that my identity 
will not be disclosed without consent 
• I understand that the information provided will only be used for the purposes of this research 
project, and I understand how the information is to be used 
• I understand that I am free to withdraw from further participation at any time, without 
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explanation or penalty 
• I freely agree to participate in the project 
 
 
 
 
Participant Name                                                       Date (DD/MM/YYYY) _______________                                                
 
Researchers Name                                                      Date (DD/MM/YYYY)                        ___y 
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APPENDIX D: STUDY 1 - MEDICAL QUESTIONNAIRE 
Medical Questionnaire                 
 
Project Title: Effects of pulsed electromagnetic field therapy on symptoms associated with 
eccentric exercise induced muscle damage. 
 
The following questionnaire is designed to establish a background of your medical history, and 
identify any injury and/or illness that may influence your testing and performance. Please answer all 
questions as accurately as possible, and if you are unsure about any aspect of this form, please ask 
for clarification. All information provided is strictly confidential.  
 
Personal Details 
  
Name: _____________________________________  
Date of Birth (DD/MM/YYYY): __________________ Gender: Male / Female  
 
 
PART A YES / NO DETAILS  
1. Are you a male over 45 years, or female over 55 years, who has had a hysterectomy or are 
postmenopausal?                                                                             Y / N _________________ 
2. Are you a regular smoker, or have you quit in the last 6 months? Y / N _______________ 
3. Did a close family member have heart disease or surgery, or stroke before the age of 60 years?                                                                                              
Y / N _________________ 
4. Do you have, or have you ever been told you have blood pressure above 140/90 mmHg, or do 
you currently take blood pressure medication?                     Y / N _________________ 
5. Do you have, or have you ever been told you have a total cholesterol level above 5.2 mmol/L 
(200 mg/dL)?                                                                    Y / N _________________ 
6. Is your BMI (weight/height) greater than 30?                            Y / N _________________  
 
PART B YES / NO DETAILS  
1. Have you ever had a serious asthma attack during exercise?     Y / N _________________  
2. Do you have asthma that requires medication?                          Y / N _________________  
3. Have you had an epileptic seizure in the last 5 years?                Y / N_________________  
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4. Do you have any moderate or severe allergies?                         Y / N _________________  
5. Do you, or could you reasonably have an infectious disease?   Y / N _________________ 
6. Do you, or could you reasonably have an infection or disease that might be aggravated by 
exercise?                                                                                         Y / N _________________ 
7. Are you, or could you reasonably be pregnant?                         Y / N _________________  
 
 
PART C YES / NO DETAILS  
1. Are you currently taking any prescribed or non-prescribed medication?                                           
Y / N __________________________________ 
2. Have you had, or do you currently have any of the following:-  
• Rheumatic Fever      Y / N _________________  
• Heart Abnormalities Y / N _________________  
• Diabetes                    Y / N _________________  
• Epilepsy                    Y / N _________________  
• Recurring back pain that will make exercise problematic, or where exercise may aggravate 
pain?                                     Y / N _________________   
• Recurring neck pain that will make exercise problematic, or where exercise may aggravate 
pain?                                     Y / N _________________ 
• Neurological disorders that would make exercise problematic, or where exercise may 
aggravate the condition?                       Y / N _________________ 
• Neuromuscular disorders that would make exercise problematic, or where exercise may 
aggravate the condition?               Y / N _________________ 
• Recurring muscle/joint injuries that would make exercise problematic, or where exercise 
may aggravate the condition? Y / N _________________ 
• A burning or cramping sensation in your legs when walking short distances?                                                               
                                                                    Y / N _________________ 
• Chest discomfort, unreasonable breathlessness, dizziness or fainting, or blackouts during 
exercise?                                    Y / N _________________ 
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PART D YES / NO DETAILS  
 
1. Have you had any influenza in the last week?                            Y / N _________________  
2. Do you currently have an injury that might affect, or be affected by exercise?  
                                                                                                        Y / N _________________ 
3. Have you had any minor or major injuries in the past 3 months? Y / N _______________ If so, 
please list. Has this injury stopped you training or competing in one or more sessions? If so, how 
many? _________________  
4. Is there any other condition not previously mentioned that may affected your ability to  
participate in this study?                                                                 Y / N _________________   
 
Declaration – (to be signed in the presence of the researcher)  
I acknowledge that the information provided in this form, is to the best of my knowledge, a true and 
accurate indication of my current state of health.  
 
Participant  
Name: __________________________________ Date (DD/MM/YYYY): _______________  
Signature: _________________________________________________________________  
 
Researcher  
Name: __________________________________ Date (DD/MM/YYYY): _______________  
Signature: _________________________________________________________________  
 
Practitioner (only if applicable)  
I, Dr _______________________________ have read the medical questionnaire and the 
information / consent form provided to my patient, Mr / Miss / Ms / Mrs _________________ 
__________________, and clear him / her medically for involvement in exercise testing.  
Name: ________________________________Date(DD/MM/YYYY):____________  
 
Signature:_____________________________________________________________ 
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APPENDIX E: STUDY 2 - INFORMATION LETTER 
Information Letter to Participants               
 
Title of the Project: Effects of Pulsed Electro Magnetic Field Therapy on Symptoms 
Associated with Eccentric Exercise-Induced Muscle Damage. 
Study 2 
Investigator: Henry Banyard (MSc. Candidate) 
Supervisor: Professor Ken Nosaka 
 
School of Exercise, Biomedical and Health Sciences 
Edith Cowan University 
270 Joondalup Drive, Joondalup WA 6027 
 
Thank you for expressing an interest in the study. The purpose of this information letter is to 
provide you with an overview of the study in which you may participate in as a subject. 
 
Purpose of the study 
We are interested in investigating the potential effect of e-cell™ treatment in reducing changes of 
muscle damage markers such as maximal voluntary contraction (MVC) strength, upper arm 
circumference, range of motion (ROM), muscle soreness, and plasma creatine kinase (CK) activity 
following eccentric exercise of the elbow flexors. 
 
Background 
Pulsed electro magnetic field therapy (PEMFT) is a therapeutic treatment that produces magnetic 
waves to penetrate deeply through tissues without contact, where the magnetic pulses are believed 
to enhance cellular repair. Previous research has shown PEMFT to reduce pain, swelling and 
inflammation relating to musculoskeletal injuries, and enhance the tissue regeneration process. A 
portable PEMFT device called e-cell™ produces low frequency, low power electromagnetic fields, 
and has been anecdotally claimed to enhance the healing processes of muscle injuries. However, no 
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experimental studies have yet examined the effects of e-cell™ treatment on markers of muscle 
damage induced by maximal elbow extension (eccentric) exercise. Therefore this will be the first 
study to investigate whether 30 minutes of e-cell™ treatment performed 30 minutes, 1, 2, 3 and 4 
days after eccentric exercise of the elbow flexors will reduce the associated symptoms and markers 
of eccentric exercise-induced muscle damage. 
 
Subjects 
As a volunteer, you must be aged between 18 to 45 years for this study. You must complete an 
informed written consent form and a medical questionnaire before participating in the study. 
Female subjects will also be asked to complete a menstrual history questionnaire. You are also 
requested not to perform unaccustomed exercise during the experimental period. 
Participants are required to attend 16 sessions consisting of a familiarisation session (45 mins), a 
reliability testing session (30 mins), 2 exercise sessions (180 mins/session) and 12 testing sessions 
(90 mins/session) at Edith Cowan University, Joondalup Campus, commencing in the exercise 
physiology lab, building 19, room 19.150.  
 
Familiarisation session:  
You will attend a familiarisation session at least one week before you participate in the study. Your 
height and weight measurements will be recorded and you will complete a medical questionnaire to 
ensure you do not present contraindications to participate in the study. You will perform 2 maximal 
static (isometric) contractions at 90˚ and 2 maximal elbow flexion (concentric) contractions at a 
velocity of 30˚·s− and 210˚·s− during this session. No elbow extension (eccentric) contractions 
will be performed to minimise any muscle damage to the elbow flexors. However you will be 
shown and briefed on the eccentric exercise protocol. Measurements such as range of motion, arm 
circumference, muscle soreness and pressure pain threshold and plasma CK activity will also be 
recorded. 
 
 
Exercise Day 
A company will provide two identical e-cell™ devices; one being the actual e-cell™ and the other 
will not generate electromagnetic pulses (sham).  Subjects will perform a bout of maximal eccentric 
exercise of the elbow flexors of each arm 4 weeks apart. Female subjects will perform the exercise 
after the luteal phase (lowest oestrogen levels) of their menstrual cycle, since oestrogen may have 
an apparent protective effect on skeletal muscle and may therefore reduce the markers of eccentric 
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exercise-induced muscle damage (Kendall & Eston, 2002). One arm will receive e-cell™ treatment 
and the other arm will receive sham treatments on five occasions such as 30 minutes after the 
exercise, and 1, 2, 3 and 4 days following the exercise. The treatment duration for each time point 
will be 30 minutes, which is normally used in the e-cell™ treatment. To establish intra-rater 
reliability for all dependant variables, two baseline measures will be taken at 3 days prior to and 
immediately before the first eccentric exercise bout. Therefore the experiment period will include 
one block of 8 days of testing (3 days before exercise, before and after exercise, 1, 2, 3, 4, 5, and 7 
days post exercise) and one block of 7 days of testing (before and after exercise, 1, 2, 3, 4, 5, and 7 
days post exercise). In the testing, isokinetic and isometric strength, range of motion, arm 
circumference, muscle soreness and pressure pain threshold, and blood samples to assess plasma 
CK activity will be taken. 
The exercise session consists of 10 sets of 6 maximum voluntary eccentric contractions of the 
elbow flexors against the lever arm of the isokinetic dynamometer moving at a constant velocity of 
30˚·s−. You will be positioned on a seated preacher arm curl bench with a supinated forearm 
position. The elbow joint will be forcibly extended from a flexed position (90˚) to a fully extended 
position (180˚) in 3 seconds. Subjects will be verbally encouraged to generate a maximal isometric 
force at the starting position and to maximally resist against the elbow extending action throughout 
the full range of motion. After each eccentric action, the isokinetic dynamometer will return the arm 
to the flexed position while you are asked to relax the arm at a constant velocity of 9˚·s−, creating a 
10 second passive recovery between contractions. The rest period between sets will be 90 seconds.  
A company (Global Energy Medicine) has provided two e-cell devices that generate 
electromagnetic pulses at different frequencies. You and the investigator are blinded to the devices 
(you are only informed of Device A and Device B).  
 
 
Recovery Day 
The recovery session days will involve a series of assessments that will be performed before and 
immediately after e-cell™ treatment. During the testing session one arm will receive e-cell™ 
treatment at a particular frequency and for the other testing session the opposite arm will receive e-
cell™ treatment at a different frequency. You will be asked to lay supine on a massage table and 
required to keep your treatment arm as still as possible until the treatment period concludes to 
minimise changes in blood flow due to movements. The device (similar in shape and size to a 
computer mouse and weighing approximately 100g) will be placed on the outside of your biceps 
brachii muscle (longitudinally along the lateral aspect of your biceps brachii) and held in place by a 
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Velcro strap. The treatment will be applied for 30 min. The device will be switched on, where green 
and red lights will flash to indicate it is operating and then turned off.  
 
Measurements 
The following measurements will be taken from the exercise arm. 
1. Maximal Static (Isometric) Strength: You will be asked to perform two 3-s maximal 
isometric contractions at an elbow joint angle of 90˚, 120˚ and 150˚ (where 180˚ represents a 
fully extended elbow joint angle) on the dynamometer in this order with 30 seconds rest 
between contractions at the same joint angle and 60 seconds rest between contractions at 
different joint angles.  
2. Range of Motion: A plastic goniometer will be used to examine the range of motion (ROM) 
of the elbow joint. Three types of joint angles will be measured; relaxed elbow joint angle 
(arm relaxed by side), extended elbow joint angle (maximal arm extension without moving 
the elbow) and flexed elbow joint angle (maximal arm flexion without moving elbow). 
ROM measurement is calculated by subtracting flexed elbow joint angle from extended 
elbow joint angle. 
3. Upper Arm Circumference: A constant tension tape will be used to measure 
circumference of the exercise limb while the arm is hanging relaxed by your side (palms 
facing the thigh). The measurements will be taken from 3 upper arm sites and 1 forearm site 
marked by a semi-permanent ink marker. 
4. Muscle Soreness: The level of muscle soreness will be assessed using a 100 mm visual 
analogue scale (VAS). On the scale, 0 mm indicates no pain and 100 mm represents extreme 
pain. You will be asked to mark your level of perceived soreness on the VAS while the 
corresponding joint is flexed and extended by the investigator. Palpation will also be applied 
using the index and middle fingers slowly in a circular motion 5 times on four sites of the 
upper arm including the mid-belly of the biceps brachii, 3 cm above and below the mid-
belly and the brachialis.  
5. Pressure Pain Threshold (PPT): A device (electronic algometer) will be used to measure 
pain in the exercised arm. Force will be gradually applied until you report the first feeling of 
noticeable pain.  
6. Plasma CK activity: A small amount of blood (30 µl) will be collected from your finger 
and the blood will be analysed for plasma CK levels. 
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Potential Risks 
You may experience some degree of muscle soreness and decreases in muscle strength and ROM 
for some days after exercise which may affect daily activities, therefore care must be taken. You 
may also experience swelling of the upper arm and forearm. These are typical symptoms of 
unaccustomed eccentric exercise induced muscle damage and will disappear in a week or so. If 
symptoms exist for longer than a week you should inform the investigator who will provide you 
with a letter explaining the study you participated in which can be presented to a doctor.  
 
Potential Benefits 
The potential benefits include the chance to observe how research is performed and gaining an 
insight and understanding about the test involved.   
 
Privacy and Confidentiality 
All information collected during this research remains confidential and will not be used for any 
other purpose other than this study. All data collected will be stored securely on ECU premises and 
kept for 5 years after the completion of the project and then destroyed. 
 
Participation in the Study 
Participation in this research is entirely voluntary and you may refuse to participate or withdraw at 
anytime without adverse consequences. 
If you have any questions about the research project or require further information you may contact 
the following:  
 
Student Researcher: Harry Banyard  
Telephone: (08) 6 304 5156  
Email: h.banyard@ecu.edu.au  
 
Principal Supervisor: Prof. Ken Nosaka  
Telephone: (08) 6 304 5655 
Email: k.nosaka@ecu.edu.au 
 
Co-Supervisor: Associate Prof. Michael Newton  
Telephone: (08) 6 304 4132 
Email: m.newton@ecu.edu.au 
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If you have any ethical concerns with regards to your participation in this study you may contact:  
 
Research Ethics Officer: Kim Gifkins   
Phone: (08) 9304 2170  
Address: Human Research Ethics Committee, Edith Cowan University, 100 Joondalup Drive, 
Joondalup WA, 6027 
Email: research.ethics@ecu.edu.au  
 
Thank you for your time,  
 
Yours sincerely,  
 
Harry Banyard 
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APPENDIX F: STUDY 2 - INFORMED CONSENT FORM 
Subject Informed Consent Form                  
Study 2 
 
I ___________________________, consent to participating in the research project entitled: 
“Effects of Pulsed Electro Magnetic Field Therapy on Symptoms Associated 
with Eccentric Exercise-Induced Muscle Damage”.  
 
Statement indicating consent to participate 
I confirm the following: 
• I have been provided with the “Information Letter” explaining the research study 
• I have read and understood the information provided and the procedures of the study 
• I have been given an opportunity to ask questions and I have had any questions answered to 
my satisfaction 
• I am aware that if I have any additional questions, I can contact the research team 
• I understand that I may experience severe muscle pain in the days after exercise 
• I am aware that my muscles will be weak for a week or two, or more than a month in rare 
instances, which may affect the performance of daily activities 
• I am aware that my muscles may be swollen for several days after exercise 
• I understand that my information provided will be kept confidential, and that my identity 
will not be disclosed without consent 
• I understand that the information provided will only be used for the purposes of this research 
project, and I understand how the information is to be used 
• I understand that I am free to withdraw from further participation at any time, without 
explanation or penalty 
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• I freely agree to participate in the project 
 
 
 
 
 
Participant Name                                                       Date (DD/MM/YYYY)                         y                        
 
Researchers Name                                                      Date (DD/MM/YYYY)                        y 
 
Signatures (Participant) _____________________ (Researcher) ____________________ 
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APPENDIX G: STUDY 2 - MEDICAL QUESTIONNAIRE 
Medical Questionnaire                 
 
The following questionnaire is designed to establish a background of your medical history, and 
identify any injury and/or illness that may influence your testing and performance. Please answer all 
questions as accurately as possible, and if you are unsure about any aspect of this form, please ask 
for clarification. All information provided is strictly confidential.  
 
Personal Details 
 
Name:______________________________________________ 
 
Date of Birth (DD/MM/YYYY):__________________ Gender: Female/ Male 
 
PART A                         Yes   /   No                     DETAILS 
       
1. Are you a male or female over the age    Y          N         _____________________ 
of 45 years?  
 
2. Are you a regular smoker or have you Y         N         _____________________ 
quit in the last 6 months? 
   
3. Did a close family member have heart Y         N         _____________________ 
disease or surgery, or stroke before  
the age of 60 years? 
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4. Do you have, or have you ever been Y         N         _____________________ 
told you have blood pressure above  
140/90 mmHg, or do you current take  
blood pressure medication?  
 
5. Do you have, or have you ever been Y         N         _____________________ 
told you have, a total cholesterol level  
above 5.2 mmol/L (200 mg/dL)?  
 
6. Is your BMI (weight/height2) greater  Y         N         _____________________ 
than 30 kg/m2? 
 
PART B 
 
1. Have you ever had a serious asthma  Y N _____________________ 
attack during exercise? 
 
2. Do you have asthma that requires  Y N         _____________________ 
medication? 
3. Have you had an epileptic seizure in  Y N _____________________ 
the last 5 years? 
4. Do you have any moderate or severe Y N _____________________ allergies? 
 
5. Do you, or could you reasonably, have  Y N _____________________ 
an infectious disease? 
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6. Do you, or could you reasonably, have  Y N _____________________ 
an infection or disease that might be  
aggravated by exercise? 
 
7. Are you currently taking contraceptive    Y N _____________________ 
tablets? 
 
8. Are you, or could you reasonably be  Y N _____________________ 
pregnant? 
      
PART C 
 
1.  Are you currently taking any prescribed or non-prescribed medications? 
 
      Y N _____________________ 
 
2.  Have you had, or do you currently have, any of the following? 
                                  DETAILS 
 
• Rheumatic fever    Y N _____________________ 
 
• Heart abnormalities   Y N _____________________ 
 
• Diabetes     Y N _____________________ 
 
• Epilepsy     Y N _____________________ 
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• Recurring back pain that would make Y N _____________________ 
exercise problematic, or where exercise  
may aggravate the pain    
 
• Recurring neck pain that would make Y N _____________________ 
exercise problematic, or where exercise  
may aggravate the pain 
 
• Any neurological disorders that would Y N _____________________ 
make exercise problematic, or where  
exercise may aggravate the condition 
 
• Any neuromuscular disorders that would Y N _____________________ 
make exercise problematic, or where  
exercise may aggravate the condition 
 
• Recurring muscle or joint injuries that Y N _____________________ 
would make exercise problematic, or  
where exercise may aggravate the  
condition  
 
• A burning or cramping sensation in your Y N _____________________ 
legs when walking short distances 
 
• Chest discomfort, unreasonable  Y N _____________________ 
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breathlessness, dizziness or fainting, 
or blackouts during exercise 
 
PART D 
 
Have you had flu in the last week?  Y N _____________________ 
 
Do you currently have an injury that might  Y N _____________________ 
affect, or be affected by, exercise?   
 
*Is there any other condition not previously mentioned that may affect your ability to participate in 
this study? 
 
Y N _________________________________________________________  
 
PART E (Female Subject) 
 
Oestrogen may have a protective effect on muscle damage and could potentially reduce the markers 
of eccentric exercise-induced muscle damage. Therefore the purpose of the following questions is 
to determine the most suitable testing period for female subjects.  
 
• Are you currently taking birth control pills / estrogen pills?    Y     N_____________ 
• If yes, what type? ________________________  
• Date of your last two menstrual cycles?                                            _____________________       
_____________________ 
 
Declaration – (to be signed in the presence of the researcher)  
I acknowledge that the information provided in this form, is to the best of my knowledge, a true and 
accurate indication of my current state of health.  
 
Participant  
Name: __________________________________ Date (DD/MM/YYYY): ______________ 
Signature: _________________________________________________________________  
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Researcher  
Name: __________________________________ Date (DD/MM/YYYY): ______________  
Signature: _________________________________________________________________  
 
Practitioner (only if applicable)  
I, Dr _______________________________ have read the medical questionnaire and the 
information / consent form provided to my patient, Mr / Miss / Ms / Mrs _________________ 
__________________, and clear him / her medically for involvement in exercise testing.  
Name: ________________________________Date(DD/MM/YYYY):____________  
Signature:_______________________________________________________________ 
 
 	  	  	  	  
 
